ank=20250708253084:20250708253308

ÅRSREDOVISNING

för

AniCura Sweden AB

Org.nr. 556586-2702

Styrelsen får härmed avlämna årsredovisning för räkenskapsåret 2024-01-01 - 2024-12-31

Innehåll **Sida**

- förvaltningsberättelse 2
- resultaträkning 4
- balansräkning 5
- noter 7
- underskrifter 24

Undertecknad styrelseledamot i AniCura Sweden AB intygar härmed, dels att denna kopia av årsredovisningen överensstämmer med originalet, dels att resultat- och balansräkning fastställts på årsstämma den 30 juni 2025. Stämman beslöt tillika godkänna styrelsens förslag till vinstdisposition.

Linköping 2025-06-30

Anna Kristell

ank=20250704-20250708253O9

ÅRSREDOVISNING

för

AniCura Sweden AB

Org.nr. 556586-2702

Styrelsen får härmed avlämna årsredovisning för räkenskapsåret 2024-01-01 - 2024-12-31

Innehåll	**Sida**
- förvaltningsberättelse	2
- resultaträkning	4
- balansräkning	5
- noter	7
- underskrifter	24

ank=20250704-20250704310

AniCura Sweden AB
Org.nr. 556586-2702

FÖRVALTNINGSBERÄTTELSE

Årsredovisningen är upprättad i svenska kronor, KSEK.

Verksamheten
Bolaget bedriver djurvård med inriktning på smådjur.

Bolaget är ett helägt dotterbolag till AniCura AB (556854-1386). Med stöd av ÅRL 7 Kap 2§ upprättas inte någon koncernredovisning i Anicura AB. Koncernredovisningen upprättas av Mars Pet Services UK Limited, company number 10517852.

Moderbolaget har sitt säte i Stockholm, Sverige.

Företagets säte är Linköping.

Flerårsjämförelse*

Beloppen i Flerårsjämförelse visas i MSEK

	2024	2023	2022	2021	2020
Nettoomsättning	1 372	1 386	14	13	10
Res. efter finansiella poster	106	106	0	-2	-1
Balansomslutning	517	517	4	6	6
Soliditet (%)	44,62	34,95	11,16	11,98	15,24
Antal anställda	1158	1228	13	12	12

*Definitioner av nyckeltal, se noter

Väsentliga händelser under räkenskapsåret
Bolaget har under december månad förvärvat Öresunds Veterinärklinik i Lund AB, organisationsnummer 559053-3153.
Vidare har bolaget under året mottagit ett ovillkorat aktieägartillskott från AniCura AB, organisationsnummer 556854-1386, om 56 454 402,94 SEK.

Förväntad framtida utveckling samt väsentliga risker och osäkerhetsfaktorer
Bolaget förväntar sig en god utveckling då efterfrågan på högkvalitativ djursjukvård inte bedöms minska. Rådande världsläge och makroekonomiska faktorer kan dock ha en något dämpande effekt på efterfrågan, åtminstone avseende specifika typer av behandlingar.

Förändringar i eget kapital

	Aktiekapital	Övrigt bundet eget kapital	Övrigt fritt eget kapital	Årets resultat	Summa fritt eget kapital
Belopp vid årets ingång	100	28	180 629	-64	180 565
Fond för utvecklingsutgifter		-8	8		8
Erhållna aktieägartillskott			56 454		56 454
Resultatdisp. enl. beslut av årsstämma:			-64	64	0
Årets förlust				-6 514	-6 514
Belopp vid årets utgång	100	20	237 027	-6 514	230 513

ank=20250704-20250708253111

AniCura Sweden AB

Org.nr. 556586-2702

Resultatdisposition (kronor)

Förslag till disposition av bolagets vinst

Till årsstämmans förfogande står	
balanserad vinst	237 027 831
årets förlust	-6 513 922
	230 513 909
Styrelsen föreslår att	
i ny räkning överföres	230 513 909
	230 513 909

Beträffande bolagets resultat och ställning i övrigt hänvisas till efterföljande resultat- och balansräkningar med tillhörande noter.

ank=20250704-20250708253312

AniCura Sweden AB
Org.nr. 556586-2702

RESULTATRÄKNING

	Not	2024-01-01 2024-12-31	2023-01-01 2023-12-31
Rörelsens intäkter m.m.			
Nettoomsättning		1 371 523	1 385 586
Övriga rörelseintäkter		26 155	24 934
		1 397 678	1 410 520
Rörelsens kostnader			
Råvaror och förnödenheter		-32 526	-35 847
Handelsvaror		-156 545	-160 300
Övriga externa kostnader		-271 333	-276 577
Personalkostnader	3	-798 981	-799 346
Av- och nedskrivningar av materiella och immateriella anläggningstillgångar		-32 406	-35 374
Övriga rörelsekostnader		-282	-2 204
		-1 292 073	-1 309 648
Rörelseresultat		105 605	100 872
Resultat från finansiella poster			
Övriga ränteintäkter och liknande resultatposter	4	369	442
Övriga ränteintäkter från koncernföretag	4	856	5 972
Räntekostnader och liknande resultatposter	5	-1 156	-1 438
		69	4 976
Resultat efter finansiella poster		105 674	105 848
Bokslutsdispositioner			
Lämnade koncernbidrag		-112 185	-106 306
		-112 185	-106 306
Resultat före skatt		-6 511	-458
Skatt på årets resultat		-3	394
Årets resultat		**-6 514**	**-64**

ank=20250704-20250708825313

AniCura Sweden AB
Org.nr. 556586-2702

BALANSRÄKNING

	Not	2024-12-31	2023-12-31
TILLGÅNGAR			
Anläggningstillgångar			
Immateriella anläggningstillgångar			
Balanserade utgifter för utvecklingsarbeten och liknande arbeten	6	0	8
Summa immateriella anläggningstillgångar		0	8
Materiella anläggningstillgångar			
Byggnader och mark	7	110 739	113 635
Förbättringsutgifter på annans fastighet	8	60 858	66 420
Maskiner och andra tekniska anläggningar	9	41 123	35 489
Inventarier, verktyg och installationer	10	6 991	5 707
Pågående nyanläggningar och förskott avseende materiella anläggningstillgångar	11	12 243	6 177
Summa materiella anläggningstillgångar		231 954	227 428
Finansiella anläggningstillgångar			
Andelar i dotterbolag	12	160 314	79 695
Andra långfristiga värdepappersinnehav		1 430	1 430
Uppskjuten skattefordran	13	5 003	4 782
Summa finansiella anläggningstillgångar		166 747	85 907
Summa anläggningstillgångar		398 701	313 343
Omsättningstillgångar			
Varulager m.m.			
Handelsvaror		28 704	29 978
Summa varulager m.m.		28 704	29 978
Kortfristiga fordringar			
Kundfordringar		19 500	18 998
Fordringar hos koncernföretag		47 725	144 851
Övriga fordringar		4 970	1 875
Förutbetalda kostnader och upplupna intäkter		10 356	7 809
Summa kortfristiga fordringar		82 551	173 533
Kassa och bank			
Kassa och bank		6 814	25
Summa kassa och bank		6 814	25
Summa omsättningstillgångar		118 069	203 536
SUMMA TILLGÅNGAR		**516 770**	**516 879**

ank=20250704-20250708:25314

AniCura Sweden AB
Org.nr. 556586-2702

BALANSRÄKNING

	Not	2024-12-31	2023-12-31
EGET KAPITAL OCH SKULDER			
Eget kapital			
Bundet eget kapital			
Aktiekapital		100	100
Reservfond		20	20
Fond för utvecklingsutgifter		0	8
Summa bundet eget kapital		120	128
Fritt eget kapital			
Balanserat resultat		237 027	180 629
Årets resultat		-6 514	-64
Summa fritt eget kapital		230 513	180 565
Summa eget kapital		230 633	180 693
Avsättningar			
Övriga avsättningar och liknande förpliktelser	12	24 391	0
Uppskjuten skatteskuld	13	2 842	2 618
Summa avsättningar		27 233	2 618
Kortfristiga skulder			
Leverantörsskulder		45 371	40 246
Skulder till koncernföretag		117 903	155 950
Aktuell skatteskuld		2 635	11 866
Övriga skulder		36 614	59 303
Upplupna kostnader och förutbetalda intäkter		56 381	66 203
Summa kortfristiga skulder		258 904	333 568
SUMMA EGET KAPITAL OCH SKULDER		516 770	516 879

NOTER

Not 1 Redovisnings- och värderingsprinciper

Årsredovisningen är upprättad i enlighet med årsredovisningslagen och BFNAR 2012:1 Årsredovisning och koncernredovisning.

Principerna är oförändrade jämfört med föregående år.

Fusion
Fusionen redovisas i enlighet med BFNAR 2020:5. Övertagna tillgångar och skulder redovisas till koncernmässiga värden. Den fusionsdifferens som uppstår redovisas direkt mot eget kapital i det övertagande bolaget.

Fordringar
Fordringar har upptagits till de belopp varmed de beräknas inflyta.

Övriga tillgångar, avsättningar och skulder
Övriga tillgångar, avsättningar och skulder har värderats till anskaffningsvärden om inget annat anges nedan.

Intäktsredovisning
Inkomsten redovisas till det verkliga värdet av vad som erhållits eller kommer att erhållas. Företaget redovisar därför inkomsten till nominellt värde (fakturabelopp) om ersättningen erhålls i likvida medel direkt vid leverans. Avdrag görs för lämnade rabatter.

Koncernbidrag och aktieägartillskott
Huvudregel för redovisning av koncernbidrag enligt 35 kap. inkomstskattelagen (1999:1229).

Koncernbidrag som erhållits/lämnats redovisas som en bokslutsdisposition i resultaträkningen. Det erhållna/lämnade koncernbidraget har påverkat företagets aktuella skatt.

Aktieägartillskott som erhållits utan att emitterade aktier eller andra egetkapitalinstrument lämnats i utbyte redovisas direkt i eget kapital.

Bokslutsdispositioner
Förändringar av obeskattade reserver redovisas som bokslutsdispositioner i resultaträkningen.

Koncernbidrag redovisas som bokslutsdispositioner.

Materiella anläggningstillgångar
Materiella anläggningstillgångar redovisas till anskaffningsvärde med avdrag för ackumulerade avskrivningar och eventuella nedskrivningar. Tillgångarna skrivs av linjärt över tillgångarnas bedömda nyttjandeperiod förutom mark som inte skrivs av. Nyttjandeperioden omprövas per varje balansdag. Följande nyttjandeperioder tillämpas:

	Antal år
Byggnader	15-100
Maskiner och andra tekniska anläggningar	5-10
Inventarier, verktyg och maskiner	5-10
Förbättringsutgifter på annans fastighet	10-20
Markanläggningar	20

Operationell leasingavtal
Leasingavgifter enligt operationella leasingavtal, inklusive förhöjd förstagångshyra med exklusive utgifter för tjänster som försäkring och underhåll, redovisas som kostnad linjärt över leasingperioden.

ank=20250704-20250708025315

ank=20250704-20250708253316

NOTER

Immateriella anläggningstillgångar
Immateriella anläggningstillgångar redovisas till anskaffningsvärde med avdrag för ackumulerade avskrivningar och eventuella nedskrivningar. Tillgångarna skrivs av linjärt över tillgångarnas bedömda nyttjandeperiod. Nyttjandeperioden omprövas per varje balansdag. Pågående projekt skrivs inte av utan nedskrivningsprövas årligen. Följande nyttjandeperioder tillämpas:

	Antal år
Balanserade utgifter för utvecklingsarbeten och liknande arbeten	5
Koncessioner, patent, licenser, varumärken samt liknande rättigheter	5

Varulager
Varulagret är värderat till det lägsta av anskaffningsvärdet, beräknat enligt först-in-först-ut, och nettoförsäljningsvärde. Nettoförsäljningsvärdet har beräknats till försäljningsvärdet efter avdrag för beräknad försäljningskostnad.

NOTER

Inkomstskatt
Aktuell skatt är inkomstskatt för innevarande räkenskapsår som avser årets skattepliktiga resultat och den del av tidigare räkenskapsårs inkomstskatt som ännu inte har redovisats.
Aktuell skatt värderas till det sannolika beloppet enligt de skattesatser och skatteregler som gäller på balansdagen.

Avsättningar
Avsättningar redovisas när det finns en legal eller informell förpliktelse till följd av en tidigare händelse, det är sannolikt att ett utflöde av resurser kommer att krävas för att reglera förpliktelsen och beloppen kan uppskattas på ett tillförlitligt sätt.
Tidpunkten eller beloppet för utflödet kan fortfarande vara osäker.

Avsättningar för omstruktureringar redovisas bara om en fastställd och utförlig omstruktureringsplan har utarbetats och införts, eller om företaget minst har offentliggjort planens huvuddrag till dem som berörs av den. Avsättningar redovisas inte för utgifter som hör samman med den framtida verksamheten.

En avsättning redovisas till den bästa uppskattningen av det belopp som krävs för att reglera förpliktelsen på balansdagen. Avsättningar tas endast i anspråk för de utgifter som avsättningen ursprungligen var avsedd för. Avsättningar diskonteras till sina nuvärden där pengars tidsvärde är väsentligt.

Likvida medel
Bolaget har medel på koncernkonto hos koncernens finansbolag. Dessa klassificeras som fordran eller skuld i balansräkningen.

Not 2 Uppskattningar och bedömningar

Osäkra kundfordringar
Bolaget har som osäkra kundfordringar reserverat fordringar äldre än 90 dagar, vilket bedöms motsvara individuell värdering.

Inkuranss varulager
Produkterna har relativt lång hållbarhet men bolaget är ändå utsatt för en risk att priser behöver sättas ned eller att produkter måste kasseras. Denna bedömning görs vid inventering av varulagret.

UPPLYSNINGAR TILL ENSKILDA POSTER

Not 3 Medelantal anställda	2024	2023
Medelantalet anställda bygger på av bolaget betalda närvarotimmar relaterade till en normal arbetstid.		
Medelantal anställda har varit	1 158	1 228

Not 4 Övriga ränteintäkter och liknande resultatposter	2024	2023
Ränteintäkter	369	442
Ränteintäkter koncern	856	5 972
	1 225	6 414

Not 5 Räntekostnader och liknande resultatposter	2024	2023
Räntekostnader	161	140
Räntekostnader koncern	995	1 298
	1 156	1 438

ank=20250704-20250708:25317

NOTER

Not 6	Balanserade utgifter för utvecklingsarbeten och liknande arbeten	2024-12-31	2023-12-31
	Ingående anskaffningsvärde	2 264	0
	Genom fusion	0	2 264
	Utgående ackumulerade anskaffningsvärden	2 264	2 264
	Ingående avskrivningar	-2 256	0
	Ingående avskrivningar fusion	0	-2 204
	Årets avskrivningar	-8	-52
	Utgående ackumulerade avskrivningar	-2 264	-2 256
	Utgående redovisat värde	0	8

Not 7	Byggnader och mark	2024-12-31	2023-12-31
	Ingående anskaffningsvärde	194 331	0
	Inköp	1 637	0
	Omklassificeringar	941	0
	Genom fusion	0	194 331
	Utgående ackumulerade anskaffningsvärden	196 909	194 331
	Ingående avskrivningar	-80 696	0
	Ingående avskrivningar fusion	0	-74 295
	Årets avskrivningar	-5 474	-6 401
	Utgående ackumulerade avskrivningar	-86 170	-80 696
	Utgående redovisat värde	110 739	113 635
	Redovisat värde byggnader	106 866	109 723
	Redovisat värde markanläggningar	265	305
	Redovisat värde mark	3 608	3 607
		110 739	113 635

Not 8	Förbättringsutgifter på annans fastighet	2024-12-31	2023-12-31
	Ingående anskaffningsvärde	128 493	2 417
	Inköp	1 275	1 948
	Omklassificeringar	646	0
	Genom fusion	0	124 128
	Utgående ackumulerade anskaffningsvärden	130 414	128 493
	Ingående avskrivningar	-62 073	-463
	Ingående avskrivningar fusion	0	-53 374
	Årets avskrivningar	-7 483	-8 236
	Utgående ackumulerade avskrivningar	-69 556	-62 073
	Utgående redovisat värde	60 858	66 420

ank=20250704-20250708253318

NOTER

Not 9	Maskiner och andra tekniska anläggningar	2024-12-31	2023-12-31
	Ingående anskaffningsvärde	241 965	3 204
	Inköp	19 118	4 757
	Omklassificeringar	3 215	0
	Genom fusion	0	234 004
	Utrangeringar	-21 179	0
	Utgående ackumulerade anskaffningsvärden	243 119	241 965
	Ingående avskrivningar	-206 476	-2 699
	Ingående avskrivningar fusion	0	-186 158
	Utrangeringar	21 104	0
	Årets avskrivning	-16 624	-17 619
	Utgående ackumulerade avskrivningar	-201 996	-206 476
	Utgående redovisat värde	41 123	35 489

Not 10	Inventarier, verktyg och installationer	2024-12-31	2023-12-31
	Ingående anskaffningsvärde	50 085	392
	Inköp	2 727	1 296
	Genom fusion	0	48 348
	Omklassificeringar	1 375	49
	Utrangeringar	-2 448	0
	Utgående ackumulerade anskaffningsvärden	51 739	50 085
	Ingående avskrivningar	-44 378	-222
	Ingående avskrivningar fusion	0	-41 090
	Utrangeringar	2 448	0
	Årets avskrivningar	-2 818	-3 066
	Utgående ackumulerade avskrivningar	-44 748	-44 378
	Utgående redovisat värde	6 991	5 707

Not 11	Pågående nyanläggningar och förskott avseende materiella anläggningstillgångar	2024-12-31	2023-12-31
	Ingående anskaffningsvärde	6 177	49
	Inköp	12 243	6 177
	Omklassificeringar	-6 177	-49
	Utgående ackumulerade anskaffningsvärden	12 243	6 177
	Utgående redovisat värde	12 243	6 177

Not 12 Andelar i dotterbolag

Företag Organisationsnummer	Säte	Antal/Kap. andel %	2024-12-31 Redovisat värde	2023-12-31 Redovisat värde
Rosenholm 2 Katrineholm AB		50 000	6 776	6 776
556962-2367	Stockholm	100,00%		
Odalbygden 8 Jägarvallen AB		1 000	6 165	6 165
556641-7456	Linköping	100,00%		
TTM lokalutveckling AB		50 000	9 636	9 637
556899-4031	Stockholm	100,00%		
Uppsala veterinärmottagning AB		1 000	56 891	57 117
556705-1031	Uppsala	100,00%		
Öresunds Veterinärklinik i Lund AB		500	80 846	0
559053-3153	Malmö	100,00%		
			160 314	79 695

ank=20250704-20250708025319

NOTER

Not 13 Uppskjuten skatt

	2024-12-31		
	Temporär skillnad	Uppskjuten skattefordran	Uppskjuten skatteskuld
Byggnader och mark	13 795	0	2 842
Förbättringsutgifter på annans fastighet	24 286	5 003	0
		5 003	2 842

	2023-12-31		
	Temporär skillnad	Uppskjuten skattefordran	Uppskjuten skatteskuld
Byggnader och mark genom fusion	12 707	0	2 618
Förbättringsutgifter på annans fastighet	342	71	0
Förbättringsutgifter på annans fastighet genom fusion	22 872	4 711	0
		4 782	2 618

Not 14 Avsättningar

	2024-12-31	2023-12-31
Tilläggsköpeskillingar och liknande poster	24 391	0
	24 391	0

ank=20250704-20250

NOTER

Not 15 Fusion	2024	2023
Anicura Property AB		
556962-2359		
Nettoomsättning	0	0
Rörelseresultat	0	-109
Anläggningstillgångar	0	22 578
Omsättningstillgångar	0	33
Avsättningar	0	0
Kortfristiga skulder	0	9
BGH Property AB		
559209-4212		
Nettoomsättning	0	0
Rörelseresultat	0	-1
Anläggningstillgångar	0	0
Omsättningstillgångar	0	42
Avsättningar	0	0
Kortfristiga skulder	0	0
Anicura Falu Djursjukhus AB		
556603-4061		
Nettoomsättning	0	88 476
Rörelseresultat	0	11 440
Anläggningstillgångar	0	21 201
Omsättningstillgångar	0	16 826
Avsättningar	0	565
Kortfristiga skulder	0	18 891

ank=20250704-20250708225321

NOTER

Animalen Djursjukhus AB		
556441-7060		
Nettoomsättning	0	25 789
Rörelseresultat	0	2 576
Anläggningstillgångar	0	13 721
Omsättningstillgångar	0	7 570
Avsättningar	0	19
Kortfristiga skulder	0	4 821
Anicura Djursjukhuset i Hässleholm AB		
556421-1414		
Nettoomsättning	0	81 850
Rörelseresultat	0	22 032
Anläggningstillgångar	0	33 785
Omsättningstillgångar	0	51 247
Avsättningar	0	525
Kortfristiga skulder	0	41 365

ank=20250704-20250708225322

NOTER

Not 15 Fusion	2024	2023
AC Djursjukhuset i Jönköping AB		
556547-6248		
Nettoomsättning	0	81 542
Rörelseresultat	0	12 532
Anläggningstillgångar	0	15 646
Omsättningstillgångar	0	17 298
Avsättningar	0	0
Kortfristiga skulder	0	19 383
AniCura Stockholms Regiondjursjukhus AB		
556636-5895		
Nettoomsättning	0	365 319
Rörelseresultat	0	35 596
Anläggningstillgångar	0	72 683
Omsättningstillgångar	0	54 305
Avsättningar	0	0
Kortfristiga skulder	0	81 538
Anicura Jägarvallens Djursjukhus AB		
556527-9428		
Nettoomsättning	0	25 515
Rörelseresultat	0	1 876
Anläggningstillgångar	0	1 019
Omsättningstillgångar	0	7 168
Avsättningar	0	0
Kortfristiga skulder	0	5 697

ank=20250704;20250708025323

NOTER

Anicura Djurkliniken Finspång AB		
556465-8390		
Nettoomsättning	0	0
Rörelseresultat	0	-22
Anläggningstillgångar	0	0
Omsättningstillgångar	0	234
Avsättningar	0	0
Kortfristiga skulder	0	-13
Anicura Norsholms Djursjukhus AB		
556285-0791		
Nettoomsättning	0	14 304
Rörelseresultat	0	1 341
Anläggningstillgångar	0	6 165
Omsättningstillgångar	0	1 434
Avsättningar	0	357
Kortfristiga skulder	0	2 056

NOTER

Not 15 Fusion	2024	2023
Anicura Veterinärhuset i Värnamo AB 556312-3560		
Nettoomsättning	0	0
Rörelseresultat	0	-30
Anläggningstillgångar	0	0
Omsättningstillgångar	0	404
Avsättningar	0	0
Kortfristiga skulder	0	77
AniCura Kalmarsund AB 556384-6764		
Nettoomsättning	0	82 105
Rörelseresultat	0	4 447
Anläggningstillgångar	0	24 187
Omsättningstillgångar	0	15 090
Avsättningar	0	1 160
Kortfristiga skulder	0	8 878
Anicura Arboga Djurklinik AB 556475-7267		
Nettoomsättning	0	11 433
Rörelseresultat	0	2 978
Anläggningstillgångar	0	292
Omsättningstillgångar	0	7 794
Avsättningar	0	0
Kortfristiga skulder	0	4 469

ank=20250704;20250704;20250704;

NOTER

Anicura Västra Djursjukhuset AB		
556718-4915		
Nettoomsättning	0	71 751
Rörelseresultat	0	2 438
Anläggningstillgångar	0	3 880
Omsättningstillgångar	0	8 618
Avsättningar	0	0
Kortfristiga skulder	0	9 171
Jourkliniken Hund & Katt i Örebro Län AB		
556855-7788		
Nettoomsättning	0	41 230
Rörelseresultat	0	4 055
Anläggningstillgångar	0	1 023
Omsättningstillgångar	0	17 422
Avsättningar	0	0
Kortfristiga skulder	0	11 885

NOTER

Not 15 Fusion	2024	2023
Anicura Djurkliniken i Katrineholm AB 556428-6499		
Nettoomsättning	0	13 783
Rörelseresultat	0	1 595
Anläggningstillgångar	0	881
Omsättningstillgångar	0	6 355
Avsättningar	0	0
Kortfristiga skulder	0	3 989
Anicura Strängnäs Djurklinik AB 556625-9981		
Nettoomsättning	0	14 252
Rörelseresultat	0	-1 487
Anläggningstillgångar	0	506
Omsättningstillgångar	0	850
Avsättningar	0	0
Kortfristiga skulder	0	1 847
Anicura Veterinärmottagning i Bromölla AB 556255-4583		
Nettoomsättning	0	13 466
Rörelseresultat	0	1 722
Anläggningstillgångar	0	1 145
Omsättningstillgångar	0	4 257
Avsättningar	0	0
Kortfristiga skulder	0	2 546

ank=20250704-20250705#70823327

NOTER

Not 15 Fusion	2024	2023
Anicura Värmdö Djurklinik AB		
556738-2782		
Nettoomsättning	0	22 326
Rörelseresultat	0	1 978
Anläggningstillgångar	0	13 549
Omsättningstillgångar	0	-5 150
Avsättningar	0	0
Kortfristiga skulder	0	5 684
Veterinärhuset Ängelholm AB		
556619-5284		
Nettoomsättning	0	11 103
Rörelseresultat	0	510
Anläggningstillgångar	0	387
Omsättningstillgångar	0	4 284
Avsättningar	0	0
Kortfristiga skulder	0	2 024
Aros VeterinärCentrum AB		
556899-4023		
Nettoomsättning	0	22 390
Rörelseresultat	0	2 329
Anläggningstillgångar	0	570
Omsättningstillgångar	0	10 016
Avsättningar	0	0
Kortfristiga skulder	0	4 782

ank=20250704;20250704

NOTER

AniCura Bohusläns Djursjukhus AB		
556728-5688		
Nettoomsättning	0	20 175
Rörelseresultat	0	1 709
Anläggningstillgångar	0	2 404
Omsättningstillgångar	0	9 739
Avsättningar	0	0
Kortfristiga skulder	0	8 476
Landskrona Smådjursklinik Aktiebolag		
556379-4766		
Nettoomsättning	0	11 056
Rörelseresultat	0	1 462
Anläggningstillgångar	0	274
Omsättningstillgångar	0	4 976
Avsättningar	0	0
Kortfristiga skulder	0	1 185

ank=20250704;20250708253329

NOTER

Not 15 Fusion	2024	2023
Erikslust Veterinärklinik AB		
556615-2855		
Nettoomsättning	0	10 435
Rörelseresultat	0	988
Anläggningstillgångar	0	1 064
Omsättningstillgångar	0	2 091
Avsättningar	0	0
Kortfristiga skulder	0	1 708
Blekinge Smådjursklinik AB		
556686-8567		
Nettoomsättning	0	13 275
Rörelseresultat	0	1 728
Anläggningstillgångar	0	413
Omsättningstillgångar	0	4 947
Avsättningar	0	0
Kortfristiga skulder	0	2 616
	0	1 913 638

Not 16 Definition av nyckeltal

Soliditet
Beräknas som justerat eget kapital i procent av balansomslutning.

Not 17 Väsentliga händelser efter räkenskapsårets slut

Inga betydande händelser har inträffat mellan balansdagen och datum för utfärdandet.

ank=20250704-20250708;20250708825330

AniCura Sweden AB
Org.nr: 556586-2702

NOTER

Linköping den 25 juni 2025

Fabrice Ribourg
Styrelseledamot

Anna Kristell
Styrelseledamot, ordförande

Sara Norgren
Styrelseledamot

Sandra Douglas
Styrelseledamot

Vår revisionsberättelse har lämnats den

Öhrlings PricewaterhouseCoopers AB

Axel Jonsson
Auktoriserad revisor

ank=20250704-20250708253331

ank=20250704-20250708:25332

AniCura Sweden AB
Org.nr. 556586-2702

NOTER

Linköping den 25 juni 2025

Fabrice Ribourg
Styrelseledamot

Anna Kristell
Styrelseledamot, ordförande

Sara Norgren
Styrelseledamot

Sandra Douglas
Styrelseledamot

Vår revisionsberättelse har lämnats den 27 juni 2025

Öhrlings PricewaterhouseCoopers AB

Axel Jonsson
Auktoriserad revisor

ank=20250704-20250708025333

Revisionsberättelse

Till bolagsstämman i AniCura Sweden AB, org.nr 556586-2702

Rapport om årsredovisningen

Uttalanden

Vi har utfört en revision av årsredovisningen för AniCura Sweden AB för år 2024.

Enligt vår uppfattning har årsredovisningen upprättats i enlighet med årsredovisningslagen och ger en i alla väsentliga avseenden rättvisande bild av AniCura Sweden ABs finansiella ställning per den 31 december 2024 och av dess finansiella resultat för året enligt årsredovisningslagen. Förvaltningsberättelsen är förenlig med årsredovisningens övriga delar.

Vi tillstyrker därför att bolagsstämman fastställer resultaträkningen och balansräkningen för AniCura Sweden AB.

Grund för uttalanden

Vi har utfört revisionen enligt International Standards on Auditing (ISA) och god revisionssed i Sverige. Vårt ansvar enligt dessa standarder beskrivs närmare i avsnittet Revisorns ansvar. Vi är oberoende i förhållande till AniCura Sweden AB enligt god revisorssed i Sverige och har i övrigt fullgjort vårt yrkesetiska ansvar enligt dessa krav.

Vi anser att de revisionsbevis vi har inhämtat är tillräckliga och ändamålsenliga som grund för våra uttalanden.

Styrelsens ansvar

Det är styrelsen som har ansvaret för att årsredovisningen upprättas och att den ger en rättvisande bild enligt årsredovisningslagen. Styrelsen ansvarar även för den interna kontroll som de bedömer är nödvändig för att upprätta en årsredovisning som inte innehåller några väsentliga felaktigheter, vare sig dessa beror på oegentligheter eller misstag.

Vid upprättandet av årsredovisningen ansvarar styrelsen för bedömningen av bolagets förmåga att fortsätta verksamheten. De upplyser, när så är tillämpligt, om förhållanden som kan påverka förmågan att fortsätta verksamheten och att använda antagandet om fortsatt drift. Antagandet om fortsatt drift tillämpas dock inte om styrelsen avser att likvidera bolaget, upphöra med verksamheten eller inte har något realistiskt alternativ till att göra något av detta.

Revisorns ansvar

Våra mål är att uppnå en rimlig grad av säkerhet om huruvida årsredovisningen som helhet inte innehåller några väsentliga felaktigheter, vare sig dessa beror på oegentligheter eller misstag, och att lämna en revisionsberättelse som innehåller våra uttalanden. Rimlig säkerhet är en hög grad av säkerhet, men är ingen garanti för att en revision som utförs enligt ISA och god revisionssed i Sverige alltid kommer att upptäcka en väsentlig felaktighet om en sådan finns. Felaktigheter kan uppstå på grund av oegentligheter eller misstag och anses vara väsentliga om de enskilt eller tillsammans rimligen kan förväntas påverka de ekonomiska beslut som användare fattar med grund i årsredovisningen.

En ytterligare beskrivning av vårt ansvar för revisionen av årsredovisningen finns på Revisorsinspektionens webbplats: www.revisorsinspektionen.se/revisornsansvar. Denna beskrivning är en del av revisionsberättelsen.

Rapport om andra krav enligt lagar och andra författningar

Uttalanden

Utöver vår revision av årsredovisningen har vi även utfört en revision av styrelsens förvaltning för AniCura Sweden AB för år 2024 samt av förslaget till dispositioner beträffande bolagets vinst eller förlust.

Vi tillstyrker att bolagsstämman disponerar vinsten enligt förslaget i förvaltningsberättelsen och beviljar styrelsens ledamöter ansvarsfrihet för räkenskapsåret.

Grund för uttalanden

Vi har utfört revisionen enligt god revisionssed i Sverige. Vårt ansvar enligt denna beskrivs närmare i avsnittet Revisorns ansvar. Vi är oberoende i förhållande till AniCura Sweden AB enligt god revisorssed i Sverige och har i övrigt fullgjort vårt yrkesetiska ansvar enligt dessa krav.

ank=20250704-20250704825334

Vi anser att de revisionsbevis vi har inhämtat är tillräckliga och ändamålsenliga som grund för våra uttalanden.

Styrelsens ansvar

Det är styrelsen som har ansvaret för förslaget till dispositioner beträffande bolagets vinst eller förlust. Vid förslag till utdelning innefattar detta bland annat en bedömning av om utdelningen är försvarlig med hänsyn till de krav som bolagets verksamhetsart, omfattning och risker ställer på storleken av bolagets egna kapital, konsolideringsbehov, likviditet och ställning i övrigt.

Styrelsen ansvarar för bolagets organisation och förvaltningen av bolagets angelägenheter. Detta innefattar bland annat att fortlöpande bedöma bolagets ekonomiska situation, och att tillse att bolagets organisation är utformad så att bokföringen, medelsförvaltningen och bolagets ekonomiska angelägenheter i övrigt kontrolleras på ett betryggande sätt.

Revisorns ansvar

Vårt mål beträffande revisionen av förvaltningen, och därmed vårt uttalande om ansvarsfrihet, är att inhämta revisionsbevis för att med en rimlig grad av säkerhet kunna bedöma om någon styrelseledamot i något väsentligt avseende:

- företagit någon åtgärd eller gjort sig skyldig till någon försummelse som kan föranleda ersättningsskyldighet mot bolaget, eller
- på något annat sätt handlat i strid med aktiebolagslagen, årsredovisningslagen eller bolagsordningen.

Vårt mål beträffande revisionen av förslaget till dispositioner av bolagets vinst eller förlust, och därmed vårt uttalande om detta, är att med rimlig grad av säkerhet bedöma om förslaget är förenligt med aktiebolagslagen.

Rimlig säkerhet är en hög grad av säkerhet, men ingen garanti för att en revision som utförs enligt god revisionssed i Sverige alltid kommer att upptäcka åtgärder eller försummelser som kan föranleda ersättningsskyldighet mot bolaget, eller att ett förslag till dispositioner av bolagets vinst eller förlust inte är förenligt med aktiebolagslagen.

En ytterligare beskrivning av vårt ansvar för revisionen av förvaltningen finns på Revisorsinspektionens webbplats: www.revisorsinspektionen.se/revisornsansvar. Denna beskrivning är en del av revisionsberättelsen.

Stockholm den 27/6 2025

Öhrlings PricewaterhouseCoopers AB

Axel Jonsson
Auktoriserad revisor

Docusign Envelope ID: 1890463A-7409-41D6-949B-06B8014673BF

Registered number: 10517852

MARS PET SERVICES UK LIMITED

ANNUAL REPORT AND FINANCIAL STATEMENTS

FOR THE PERIOD ENDED 28 DECEMBER 2024

MARS PET SERVICES UK LIMITED

COMPANY INFORMATION

Directors	A D Scipio Del Campo B Garish M Page
Registered number	10517852
Registered office	3d Dundee Road Slough United Kingdom SL1 4LG
Independent auditors	PricewaterhouseCoopers LLP Chartered Accountants & Statutory Auditors One Chamberlain Square Birmingham B3 3AX

Docusign Envelope ID: 1890463A-7409-41D6-949B-06B8014673BF

MARS PET SERVICES UK LIMITED

CONTENTS

	Page
Group Strategic Report	1 - 4
Directors' Report	5 - 9
Directors' Responsibilities Statement	10
Independent Auditors' Report	11 - 14
Consolidated Income Statement	15
Consolidated Statement of Comprehensive Income	16
Consolidated Balance Sheet	17
Company Balance Sheet	18
Consolidated Statement of Changes in Equity	19 - 21
Company Statement of Changes in Equity	22
Consolidated Statement of Cash Flows	23 - 24
Notes to the Financial Statements	25 - 69

MARS PET SERVICES UK LIMITED

GROUP STRATEGIC REPORT
FOR THE PERIOD ENDED 28 DECEMBER 2024

Introduction

The directors present their Strategic Report on the Company for the period ended 28 December 2024. The results represent the 52 week period ended 28 December 2024 and the comparatives represent the 52 week period ended 31 December 2023.

Business review

Strategy & Progress

The Group's strategy is to build the highest quality specialist veterinary services group in the UK and Europe through the acquisition of high-quality platforms and practices, whilst continuing to grow existing practices organically. The practices are locally branded and led by clinically focused staff benefiting from enhanced buying, marketing, training and back-office support.

Acquisitions are funded by a combination of funds from Group cash flows and shareholders' debt facilities.

Goodwill arising from acquisitions is written off over a period of 10 years which creates a large charge to the Profit and Loss account but has no effect on cash flow.

Review of the business

The period performance was significantly below plan due to several external and internal one-off factors such as slowdown in the market performance, additional costs related to consultants and contractors as well as restructuring projects. Management considers this situation as temporary and has a reasonable assurance, that business performance will be back to good level in 2025.

The results for the period which are set out in the consolidated statement of comprehensive income show group operating loss of £418,642,000 (2023: £347,505,000) after charging amortisation of goodwill of £367,834,000 (2023: £374,965,000), impairment of goodwill of £Nil (2023: £Nil) and exceptional items of £17,057,000 (2023: £12,770,000).

During the financial period, the directors have recorded an impairment charge of £1,261,000,000 to investments within the company financial statements. This impairment charge is mainly driven by general industry slowdown and consequences of Competition and Markets Authority (CMA) process. Further details are provided within Note 13 of the notes of the financial statements.

As of 28 December 2024, the Group had total assets less current liabilities of £1,712,929,000 (2023: £1,965,523,000) and net assets of £629,826,000 (2023: £970,488,000).The directors consider the financial position of the Group and Company at the period end to be satisfactory.

Section 172(1) statement

The Directors believe that they have effectively implemented their duties under section 172 of the Companies Act 2006. The Directors have considered the long-term strategy of the Group as mentioned in "Future developments" below and consider that this strategy will continue to deliver long term success for the Group's business and its stakeholders.

The Directors recognise the importance of wider stakeholders in delivering the strategy and achieving sustainability within the business. The main stakeholders in the company are considered to be the shareholders, employees, suppliers and customers. The Group follows a Five Principles approach to guide how we interact with suppliers, customers and others. We base decisions on the mutuality of benefit to our stakeholders. A mutual benefit is a shared benefit; a shared benefit will endure. The Mars Petcare website contains further guidance on our Five Principles.

Due to the nature of our business, good customer and community relations are key to the ongoing success of the Group. The Group is committed to maintaining an excellent reputation and strives to achieve high standards. As a part of this, the Group is selective in the suppliers used and aims to provide a range of pet care and veterinary services to the communities in which we operate while maintaining cost efficiencies for the benefit of our shareholders.

Employee involvement

The Group believes that it is important that all associates are closely involved in the fortunes of the business for which they work and have a clear understanding of the contribution which each should make to the realisation of that business' objectives.

Communication has continued at all levels, with the aim that all associates are aware of the financial and economic performance of the business. The Group has developed a variety of communication and discussion practices closely tailored to its needs and circumstances, the most important of these being regular briefing sessions of associates with their managers. Associates are asked to take on direct and total responsibility for results, exercising initiative and making decisions, as their tasks require.

Linking the business pay plan to its major operating and financial results further strengthens the mutuality of associates' involvement in the performance of the business. Certain employees across the Group's mainland Europe subsidiaries have been invited to join a long-term incentive plan, allowing employees the opportunity to share in the ongoing business and strategic success of the Group. These initiatives are central to providing quality service to our customers who in turn provide their ongoing support to our business.

Single status treatment of its associates is one of the hallmarks of the Group's industrial relations policy. It is an equal opportunity employer, the only criteria for selection and promotion being the skills and aptitude of the individual in relation to the particular job and needs of the business concerned.

The Group is glad to provide worthwhile employment for disabled or medically restricted persons. It is the Group's practice to identify jobs that are within the capabilities of such persons and fill them with these personnel. Should associates become disabled, it is the Group's policy to continue their employment where possible with appropriate training and redeployment where necessary.

Training and career development programmes are designed on an individual basis for all associates so that the particular needs and aptitudes of each person can best be met and developed.

In ensuring that all our stakeholders are considered as a part of every decision process we believe we act fairly and mutually between all members of the Company.

Supplier payment policy

The Group agrees terms and conditions for its business transactions with suppliers before orders are placed. Payments are then made in accordance with these obligations.

Supply chain management

The Group makes use of trusted suppliers, many of which have been used for a number of years. Where possible, the Group will seek to benefit from these close relationships and look to engineer cost efficient solutions which result in mutual benefit to the Group, the supplier as well as the customer.

Principal risks and uncertainties

The management of the business and the execution of the Group's strategy are subject to a number of risks. The key business risks and uncertainties affecting the Group are considered to relate to competition from both national and local providers of veterinary services, and to our ability to recruit and retain veterinary professionals in the business. Macroeconomic instability is impacting the demand for advanced veterinary services as well as put additional pressure on the margin due to payroll-related costs inflation.

These risks and uncertainties are managed day to day by discreet management teams responsible for each segment of the Group's business and who report to the directors. Management has an adequate set of actions to respond to the key risks business is facing.

Key performance indicators

Given the nature of the business, the Group's directors are of the opinion that key performance indicators are important. The Group uses a number of indicators to monitor and improve the development, performance and the position of the business. Indicators are reviewed and altered to meet changes in both the internal and external environments. The KPIs include gross profit percentage, EBITDA as a percentage of turnover and Return on Capital Employed (RoCE).

Gross profit percentage: 2024:15.79% (2023: 16.99%).
Gross profit decrease follows overall sales slowdown and restructuring projects happened during the period. These initiatives aim to improve clinic operational efficiency and productivity.

EBITDA as a percentage of turnover: 2024:(0.63%) (2023: 6.78%).
EBITDA reduction is driven by one-off factors impacting the performance during the period primarily related to higher contractors and consultants' fees, combined with G&A overheads optimisation initiatives.

Return on Capital employed: 2024: (24.44%) 2023: (17.75%).
The change in this ratio is mainly driven by higher operating loss explained above.

Future developments

The Group plans to slowdown acquisition activity in 2025 following situation in the market. Due to highly competitive M&A market in some European countries of operations, Group is also assessing opportunities for greenfield investments and building new hospitals. The Group has funding facilities in place to fund the planned acquisitions and greenfield initiatives through its parent company.

Objectives and policies

The board constantly monitors the Group's trading results and revise the projections as appropriate to ensure that the Group can continue to meet its future obligations as they fall due.

The Group is exposed to the usual credit and cash flow risk associated with selling on credit and manages this through credit control procedures. The group is not exposed to material price risk. The Group is able to adequately manage and monitor any cash flow risks as they arise through short term intra group assistance.

Credit risk in respect of bank balances is safeguarded by using banks with high credit ratings. The group's financial instruments are subject to liquidity risk as detailed in note 18 to the financial statements.

The Company's non-financial and sustainability information statement (NFSIS)

The directors consider that the climate-related risk and opportunities of the Company, including how they are identified, assessed and managed, are integrated with those of the Mars, Incorporated group. Mars, Incorporated's sustainability strategy is set at the group level.

The principal climate-related risks and opportunities for the Company are transitional risks associated with current and future government and regulatory measures

These have been included in the group's scenario analysis and will continue to be monitored by the directors as more information becomes available. The group (Mars, Incorporated) has set a science-based climate target in line with global alignment on 1.5 degrees Celsius goal to achieve net zero greenhouse gas (GHG) emissions across its full value chain by 2050 and published the Mars Net Zero Roadmap including a target to reduce total value chain emissions 50% by 2030 from a 2015 baseline. In support of this milestone, Mars, Incorporated will also be accountable for targets approved by the Science Based Targets Initiative (SBTi) using their latest guidance on absolute reductions for energy and industrial emissions and for Forest, Land and Agricultural (FLAG) emissions.

The Company's non-financial and sustainability information statement (NFSIS) (continued)

The climate-related risks and opportunities of the Mars, Incorporated group including related time periods and arrangements for managing them are discussed further in Mars, Incorporated's 2024 CDP Climate Change disclosure (Mars 2024 CDP report modules 2, 3 4, 5 and 7) and the Mars Net Zero Roadmap (https://www.mars.com/sustainability-plan/healthy-planet/net-zero-2050).

There are no further matters that the directors consider require disclosure in relation to parts E- H of Section 414CB of the Companies Act 2006 to understand the business.

This report was approved by the board and signed on its behalf.

DocuSigned by:
141B8E5F6E104FC...

M Page
Director

Date: 26-09-2025

MARS PET SERVICES UK LIMITED

DIRECTORS' REPORT
FOR THE PERIOD ENDED 28 DECEMBER 2024

The directors present their report and the audited consolidated financial statements for the period ended 28 December 2024.

Principal activities

The principal activity of the Group is that of provision of veterinary services.

The principal activity of the Company is that of a non-trading holding company.

Results and dividends

The loss for the period, after taxation and minority interests, amounted to £457,084,000 *(2023 - loss £422,358,000)*.

The directors do not propose a dividend in the current period or prior period.

Directors

The Directors who served during the period were:

A D Scipio Del Campo
B Garish
M Page

Employment of disabled persons

The Group's policy is to consider the recruitment of disabled workers for those vacancies that they are able to fill. All necessary assistance with initial training courses is given. Once employed, a career plan is developed so as to ensure suitable opportunities for each disabled person. Arrangements are made, wherever possible, for retraining employees who become disabled, to enable them to perform work identified as appropriate to their aptitudes and abilities.

Employee involvement

The Group encourages the involvement of employees in its management through regular departmental meetings. Further information in respect of employee involvement has been reported in the Strategic Report.

Future developments

The Group plans to continue with its strategy of acquiring high quality veterinary practices. The Group has funding facilities in place to fund the planned acquisitions. The Group is strongly cash generating before investing in additional acquisitions.

Post balance sheet events

There are no post balance sheet events to be aware of.

Going concern

The Group's business activities, together with the factors likely to affect its future development, performance and position are set out on page 2-4. The financial position of the Group, its cash flows, liquidity position and borrowing facilities are described on pages 15-24. In addition, the notes to the financial statements include the Group's objectives, policies and processes for managing its capital; its financial risk management objectives; details of its financial instruments and hedging activities; and its exposures to credit risk and liquidity risk.

The Group meets its day-to-day working capital requirements through free cash and its acquisition requirements through a loan facility from a connected company and has received a letter of support from its ultimate parent company. The Group's forecasts and projections, covering a period of at least 12 months from the approval of these financial statements, show that the Group should be able to operate within the level of its current debt facilities. The Group has plans to continue establishing the foundations of robust veterinary network via improving operating model, harmonising the systems in place, and investing in our Associates to retain the talents in the business. The Group is also working on optimizing customer experience and improving price strategy to accelerate organic growth.

Management has also considered current political instability in Europe and concluded that we do not expect substantial impact on business ability to operate due to business being setup across different countries.
The directors have undertaken a detailed impairment review under the requirements of FRS 102 and have considered a range of possible scenarios over long term revenue and profitability. Based on these scenarios and given the limited track record of the businesses the directors have recorded an impairment charge of £1,261,000,000 to investments within the company financial statements. The impairment charge is mainly driven by an increase of investments from parent company to fund the acquisition investments till the end of 2024 and negative forex effect, and as such is considered, by directors, not to be a significant risk to the going concern of the group.

In considering going concern, the directors have reviewed the cash flow requirements of the Group and Company, both under normal circumstances and reflecting the current assessment of the severe but plausible downside scenarios.

Director's indemnity

The Company maintains liability insurance for its directors and officers, which is a qualifying third party indemnity provision for the purpose of the Companies Act 2006.The indemnity was in force throughout the financial period and also at the date of approval of the financial statements.

Carbon and energy reporting

Linnaeus Veterinary Limited has adjusted the reporting period of its SECR to fit with its internal calendar. This carbon emissions report is for the financial reporting period.. The previous reporting period was from 9th October 2022 - 7th October 2023, the two reporting periods are therefore not directly comparable.

Linnaeus Veterinary Limited's greenhouse gas emissions, reportable under SECR for the year to 31 December 2024 were 6,608.4 tonnes CO2e using the Location-Based Methodology (mandatory reporting), which is an increase by 9% compared to the last report; or 119.9 tonnes CO2e using the Market-Based Methodology (voluntary reporting), which is a decrease by 57% compared to the last report.

The carbon intensity of 15.2 tonnes CO2e per £m, is similar to the last report using the Location-Based Methodology.

These include emissions associated with electricity, natural gas, propane, gas oil, kerosene and anaesthetics gas and transportation. It is not mandatory to report anaesthetics under SECR, but they have been included for transparency.

Carbon and energy reporting (continued)
Greenhouse gas emissions

Table 1: Greenhouse Gas Emission (tonnes CO2e)

Emissions source	**31 December 2024 Market based**	**31 December 2023 From 9th October 2022 to 7th October 2023 Market based**	*31 December % YOY Change*	*31 December % Share*
Fuel combustion: stationary	**1,234**	**1,386**	*-11*	*19*
Fuel combustion: mobile	**402**	**578**	*-30*	*6*
Anaesthetics	**2,229**	**1,504**	*48*	*67*
Purchased electricity	**2,744**	**2,604**	*-39*	*9*
Total emissions (tCo2e)	**6,609**	**6,071**		
Turnover (£m)	**434**	**408**		
Intensity: (tCO2e per £m)	**15.23**	**14.88**		

Table 2: Energy consumption by year (kWh)

	28 December 2024	**31 December 2023 From 9th October 2022 to 7th October 2023**	*31 December % YOY Change*	*31 December % Share*
Fuel combustion: Natural gas	**5,715,546**	**5,206,326**	*10*	*29*
Purchased electricity	**13,252,370**	**12,572,878**	*5*	*68*
Fuel combustion: Transport	**661,405**	**1,525,482**	*-57*	*3*
	-	**-**		
Total	**19,629,321**	**19,304,686**		

Carbon and energy reporting (continued)

The SECR report relates to Linnaeus Veterinary Limited covers the emissions from its operations from 1st January 2024 – 31st December 2024.

The reported carbon emissions have been calculated following the guidance in the UK Government's Environmental Reporting Guidelines, 2019, and the methodology outlined in The GHG Protocol Corporate Accounting and Reporting Standard (revised edition). Carbon Emission factors have been obtained from the UK Government's GHG Conversion Factors for Company Reporting 2024. Scope 1 travel data was not split between any fuel types, so a 50/50 split between petrol and diesel was used.

An 'operational control' methodology has been adopted to outline the scope of carbon emissions reporting for Linnaeus Veterinary Limited. Operational control refers to the ability of an organisation to direct the activities of a facility or operation. In the context of greenhouse gas (GHG) reporting, a company is considered to have operational control over a facility, if it has the authority to introduce and implement operating policies at that facility, regardless of ownership. This means the organisation is responsible for the GHG emissions from the 'operations it controls'.

Energy efficiency initiatives
With respect to energy measures, we now source 100% renewable electricity for most of our veterinary clinics in UK and Republic of Ireland. To date, Linnaeus Veterinary Limited has delivered over 6,000 Paws to Turn Off stickers to encourage reductions in electricity consumption. We have installed automatic meters in 79% of our electricity and gas meters across the estate, and monthly energy consumption data is available to our teams.

As of the end of our SECR 2024 period, 57 of our practice teams were members of the Investors in the Environment scheme and 38 were accredited: 6 at Green level including our Support Office, 19 at Silver level and the remainder at Bronze level. This scheme supports energy saving via behaviour change and leadership at site level. We funded 1,300 trees to be planted via the organisation OneTreePlanted as part of engagement measures to support sustainable behaviours.

In 2024, we launched an industry-first anaesthetic gas capture pilot in 14 Linnaeus Veterinary Limited clinics to further curb greenhouse gas emissions. We continue to purchase capnographs for our new acquisitions to support lower carbon anaesthesia, via our "We Go for Lower Flow" campaign that includes videos and posters and is open source for any external users to access.

To continue to manage our travel emissions, our salary sacrifice scheme has delivered electric cars to 64 Associates since its launch in 2022.

Despite implementing various energy-saving measures, our overall energy consumption and emissions have increased. This rise is primarily due to the expansion of our network, with approximately 15% more clinics now in operation.

Matters covered in the Group Strategic Report

Information in respect of the Group's engagement with Suppliers, Customers and Others in a Business Relationship as well as the Group's financial risk management have been reported on in the Strategic Report and in the opinion of the directors require no further input here.

Disclosure of information to auditors

Each of the persons who are directors at the time when this Directors' Report is approved has confirmed that:

- so far as the director is aware, there is no relevant audit information of which the Company and the Group's auditors are unaware, and
- the director has taken all the steps that ought to have been taken as a director in order to be aware of any relevant audit information and to establish that the Company and the Group's auditors are aware of that information.

  This confirmation is given and should be interpreted in accordance with the provisions of s418 of the Companies Act 2006.

Independent auditors

The auditors, PricewaterhouseCoopers LLP, will be proposed for reappointment in accordance with section 485 of the Companies Act 2006.

This report was approved by the Board and signed on its behalf.

DocuSigned by:
141B8E5F6E104FC...

.....

M Page
Director

Date: 26-09-2025

MARS PET SERVICES UK LIMITED

DIRECTORS' RESPONSIBILITIES STATEMENT FOR THE PERIOD ENDED 28 DECEMBER 2024

The directors are responsible for preparing the Group Strategic Report, the Directors' Report and the consolidated audited consolidated financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare audited consolidated financial statements for each financial period. Under that law the directors have elected to prepare the audited consolidated financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'. Under company law the directors must not approve the audited consolidated financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and the Group and of the profit or loss of the Group for that period.

- select suitable accounting policies and then apply them consistently;
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards, comprising FRS 102 have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Group will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and the Group and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and the Group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The directors are responsible for the maintenance and integrity of the corporate and financial information included on the Group's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements and other information included in Directors' Reports may differ from legislation in other jurisdictions.

Approved by the Board of Directors and signed on its behalf by:

DocuSigned by:
141B5E5F6E104FC...

M Page
Director
Date: 26-09-2025

Independent auditors' report to the members of Mars Pet Services UK Limited

Report on the audit of the financial statements

Opinion

In our opinion, Mars Pet Services UK Limited's group financial statements and company financial statements (the "financial statements"):

- give a true and fair view of the state of the group's and of the company's affairs as at 28 December 2024 and of the group's and company's loss and the group's cash flows for the 52 week period then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards, including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", and applicable law); and
- have been prepared in accordance with the requirements of the Companies Act 2006.

We have audited the financial statements, included within the Annual Report and Financial Statements (the "Annual Report"), which comprise: the Consolidated Balance Sheet and Company Balance Sheet as at 28 December 2024; the Consolidated Income Statement, the Consolidated Statement of Comprehensive Income, the Consolidated Statement of Changes in Equity, the Company Statement of Changes in Equity and the Consolidated Statement of Cash Flows for the period then ended; and the notes to the financial statements, which include a description of the significant accounting policies.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) ("ISAs (UK)") and applicable law. Our responsibilities under ISAs (UK) are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We remained independent of the group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, which includes the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

Conclusions relating to going concern

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

However, because not all future events or conditions can be predicted, this conclusion is not a guarantee as to the group's and the company's ability to continue as a going concern.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Reporting on other information

The other information comprises all of the information in the Annual Report other than the financial statements and our auditors' report thereon. The directors are responsible for the other information. Our opinion on the financial statements does not cover the other information and, accordingly, we do not express an audit opinion or, except to the extent otherwise explicitly stated in this report, any form of assurance thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If we identify an apparent material inconsistency or material misstatement, we are required to perform procedures to conclude whether there is a material misstatement of the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report based on these responsibilities.

With respect to the Strategic report and Directors' Report, we also considered whether the disclosures required by the UK Companies Act 2006 have been included.

Based on our work undertaken in the course of the audit, the Companies Act 2006 requires us also to report certain opinions and matters as described below.

Strategic report and Directors' Report

In our opinion, based on the work undertaken in the course of the audit, the information given in the Strategic report and Directors' Report for the period ended 28 December 2024 is consistent with the financial statements and has been prepared in accordance with applicable legal requirements.

In light of the knowledge and understanding of the group and company and their environment obtained in the course of the audit, we did not identify any material misstatements in the Strategic report and Directors' Report.

Responsibilities for the financial statements and the audit

Responsibilities of the directors for the financial statements

As explained more fully in the Directors' Responsibilities Statement, the directors are responsible for the preparation of the financial statements in accordance with the applicable framework and for being satisfied that they give a true and fair view. The directors are also responsible for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the group's and the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the group or the company or to cease operations, or have no realistic alternative but to do so.

Auditors' responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Based on our understanding of the group and industry, we identified that the principal risks of non-compliance with laws and regulations related to employment laws and regulations and health and safety legislation, and we considered the extent to which non-compliance might have a material effect on the financial statements. We also considered those laws and regulations that have a direct impact on the financial statements such as Companies Act 2006 and corporate tax legislation. We evaluated management's incentives and opportunities for fraudulent manipulation of the financial statements (including the risk of override of controls), and determined that the principal risks were related to the posting of journals with unusual account combinations or the manipulation of accounting estimates which could be subject to management bias. Audit procedures performed by the engagement team included:

- Discussions with management, including consideration of known or suspected instances of non-compliance with laws and regulation and fraud;
- Substantive testing of journal entries, particularly focused around journals which have unexpected account relationships;
- Challenging assumptions and judgements made by management in determining their accounting estimates, in particular in relation to the valuation of goodwill, investments and acquisition related liabilities;
- Review of minutes of meetings of those charged with governance; and
- Reviewing component teams' key working papers for all in-scope components with a particular focus on the areas involving judgement and estimates.

There are inherent limitations in the audit procedures described above. We are less likely to become aware of instances of non-compliance with laws and regulations that are not closely related to events and transactions reflected in the financial statements. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.

A further description of our responsibilities for the audit of the financial statements is located on the FRC's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditors' report.

Use of this report

This report, including the opinions, has been prepared for and only for the company's members as a body in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and for no other purpose. We do not, in giving these opinions, accept or assume responsibility for any other purpose or to any other person to whom this report is shown or into whose hands it may come save where expressly agreed by our prior consent in writing.

Other required reporting

Companies Act 2006 exception reporting

Under the Companies Act 2006 we are required to report to you if, in our opinion:

- we have not obtained all the information and explanations we require for our audit; or
- adequate accounting records have not been kept by the company, or returns adequate for our audit have not been received from branches not visited by us; or
- certain disclosures of directors' remuneration specified by law are not made; or
- the company financial statements are not in agreement with the accounting records and returns.

We have no exceptions to report arising from this responsibility.

Chris Hibbs

Christopher Hibbs (Senior Statutory Auditor)
for and on behalf of PricewaterhouseCoopers LLP
Chartered Accountants and Statutory Auditors
Birmingham
29 September 2025

MARS PET SERVICES UK LIMITED

CONSOLIDATED INCOME STATEMENT
FOR THE PERIOD ENDED 28 DECEMBER 2024

	Note	2024 £000	*2023 £000*
Turnover	3	**1,328,932**	*1,281,793*
Cost of sales		**(1,119,033)**	*(1,063,973)*
Gross profit		**209,899**	*217,820*
Administrative expenses		**(243,830)**	*(178,434)*
Exceptional items	4	**(17,057)**	*(12,770)*
Amortisation of goodwill	11	**(367,834)**	*(374,965)*
Share of operating profit in associate		**180**	*844*
Operating loss	5	**(418,642)**	*(347,505)*
Interest receivable and similar income		**5,676**	*419*
Interest payable and similar expenses	9	**(50,045)**	*(56,519)*
Loss before tax		**(463,011)**	*(403,605)*
Tax on loss	10	**5,894**	*(18,753)*
Loss for the financial period		**(457,117)**	*(422,358)*
(Loss) / profit for the period attributable to:			
Non-controlling interests		**(33)**	*2,173*
Owners of the parent		**(457,084)**	*(424,531)*
		(457,117)	*(422,358)*

The notes on pages 25 to 69 form part of these financial statements.

MARS PET SERVICES UK LIMITED

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE PERIOD ENDED 28 DECEMBER 2024

	2024	*2023*
	£000	*£000*
Loss for the financial period	**(457,117)**	*(422,358)*
Currency translation differences on foreign currency net investments	**(65,449)**	*46,768*
NCI Reclassifications	**(22,290)**	*35,913*
Total comprehensive expense for the period	**(544,856)**	*(339,677)*
Total comprehensive income / (expense) attributable to:		
Non-controlling interest	**(15,441)**	*38,389*
Owners of the parent Company	**(529,415)**	*(378,066)*
	(544,856)	*(339,677)*

MARS PET SERVICES UK LIMITED
REGISTERED NUMBER: 10517852

CONSOLIDATED BALANCE SHEET
AS AT 28 DECEMBER 2024

	Note	28 December 2024 £000		*31 December 2023 £000*	
Fixed assets					
Intangible assets	11		**1,361,962**		*1,564,062*
Tangible assets	12		**267,640**		*273,305*
Investments	13		**2,161**		*7*
			1,631,763		*1,837,374*
Current assets					
Stocks	14	**37,100**		*35,448*	
Debtors: amounts falling due within one year	15	**174,523**		*154,583*	
Cash at bank and in hand		**158,777**		*164,524*	
		370,400		*354,555*	
Creditors: amounts falling due within one year	16	**(289,234)**		*(226,406)*	
Net current assets			**81,166**		*128,149*
Total assets less current liabilities			**1,712,929**		*1,965,523*
Creditors: amounts falling due after more than one year	17		**(1,083,091)**		*(995,022)*
Provisions for liabilities					
Other provisions	20	**(12)**		*(13)*	
			(12)		*(13)*
Net assets			**629,826**		*970,488*
Capital and reserves					
Share premium account	22		**3,879,389**		*3,671,387*
Profit and loss account	22		**(3,258,688)**		*(2,728,671)*
Equity attributable to owners of the parent			**620,701**		*942,716*
Non-controlling interests			**9,125**		*27,772*
Total equity			**629,826**		*970,488*

The financial statements were approved and authorised for issue by the board and were signed on its behalf on

DocuSigned by:
141B8E5F8E104FC...

.....

M Page
Director

The notes on pages 25 to 69 form part of these financial statements.

MARS PET SERVICES UK LIMITED
REGISTERED NUMBER: 10517852

COMPANY BALANCE SHEET
AS AT 28 DECEMBER 2024

	Note		28 December 2024 £000		*31 December 2023 £000*
Fixed assets					
Investments	13		**1,963,867**		*3,019,586*
			1,963,867		*3,019,586*
Current assets					
Debtors: amounts falling due within one year	15	**79,106**		*187*	
		79,106		*187*	
Creditors: amounts falling due within one year	16	**-**		*(8,115)*	
Net current assets/(liabilities)			**79,106**		*(7,928)*
Total assets less current liabilities			**2,042,973**		*3,011,658*
Creditors: amounts falling due after more than one year	17		**(963,010)**		*(891,801)*
Net assets			**1,079,963**		*2,119,857*
Capital and reserves					
Share premium account	22		**3,879,389**		*3,671,387*
Profit and loss account brought forward		**(1,551,530)**		*(1,310,182)*	
Loss for the period		**(1,303,537)**		*(484,456)*	
Other changes in the profit and loss account		**55,641**		*243,108*	
Profit and loss account carried forward			**(2,799,426)**		*(1,551,530)*
			1,079,963		*2,119,857*

The financial statements were approved and authorised for issue by the board and were signed on its behalf on

DocuSigned by:
M. J. Page
141B8EEFBE104FC...

.....

M Page
Director

The notes on pages 25 to 69 form part of these financial statements.

MARS PET SERVICES UK LIMITED

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE PERIOD ENDED 28 DECEMBER 2024

	Share premium account	Profit and loss account	Equity attributable to owners of the parent	Non-controlling interests	Total equity
	£000	£000	£000	£000	£000
At 1 January 2023	**3,275,556**	**(2,348,556)**	**927,000**	**(9,198)**	**917,802**
Comprehensive (expense)/income for the period					
(Loss) / profit for the period	-	**(424,531)**	**(424,531)**	**2,173**	**(422,358)**
Currency translation differences	-	**46,465**	**46,465**	**303**	**46,768**
Prior year reclassification	-	-	-	**35,913**	**35,913**
Other comprehensive income for the period	-	**46,465**	**46,465**	**36,216**	**82,681**
Total comprehensive (expense)/income for the period	-	**(378,066)**	**(378,066)**	**38,389**	**(339,677)**
Contributions by and distributions to owners					
Dividends: Equity capital	-	**(2,049)**	**(2,049)**	**(1,420)**	**(3,469)**
Shares issued during the period	**395,831**	-	**395,831**	-	**395,831**
Total transactions with owners	**395,831**	**(2,049)**	**393,782**	**(1,420)**	**392,362**

MARS PET SERVICES UK LIMITED

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (CONTINUED)
FOR THE PERIOD ENDED 28 DECEMBER 2024

	Share premium account £000	Profit and loss account £000	Equity attributable to owners of the parent £000	Non-controlling interests £000	Total equity £000
At 31 December 2023	**3,671,387**	**(2,728,671)**	**942,716**	**27,771**	**970,487**
Comprehensive (expense)/income for the period					
(Loss) for the period	-	**(457,084)**	**(457,084)**	-	**(457,084)**
Currency translation differences	-	**(72,331)**	**(72,331)**	**6,882**	**(65,449)**
Other NCI costs- divestments	-	-	-	**(22,323)**	**(22,323)**
Other comprehensive expense for the period	-	**(72,331)**	**(72,331)**	**(15,441)**	**(87,772)**
Total comprehensive (expense) for the period	-	**(529,415)**	**(529,415)**	**(15,441)**	**(544,856)**

MARS PET SERVICES UK LIMITED

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (CONTINUED)
FOR THE PERIOD ENDED 28 DECEMBER 2024

	Share premium account £000	Profit and loss account £000	Equity attributable to owners of the parent £000	Non-controlling interests £000	Total equity £000
Contributions by and distributions to owners					
Dividends: Equity capital	-	(602)	(602)	(3,205)	(3,807)
Shares issued during the period	208,002	-	208,002	-	208,002
Total transactions with owners	208,002	(602)	207,400	(3,205)	204,195
At 28 December 2024	3,879,389	(3,258,688)	620,701	9,125	629,826

The notes on pages 25 to 69 form part of these financial statements.

MARS PET SERVICES UK LIMITED

COMPANY STATEMENT OF CHANGES IN EQUITY
FOR THE PERIOD ENDED 28 DECEMBER 2024

	Share premium account	Profit and loss account	Total equity
	£000	£000	£000
At 1 January 2023	**3,275,556**	**(1,310,182)**	**1,965,374**
Loss for the period	-	**(484,456)**	**(484,456)**
Currency translation differences	-	**243,108**	**243,108**
Total comprehensive expense for the period	-	**(241,348)**	**(241,348)**
Contributions by and distributions to owners			
Shares issued during the period	**395,831**	-	**395,831**
At 31 December 2023	**3,671,387**	**(1,551,530)**	**2,119,857**
Loss for the period	-	**(1,303,537)**	**(1,303,537)**
Currency translation differences	-	**55,641**	**55,641**
Total comprehensive expense for the period	-	**(1,247,896)**	**(1,247,896)**
Contributions by and distributions to owners			
Shares issued during the period	**208,002**	-	**208,002**
At 28 December 2024	**3,879,389**	**(2,799,426)**	**1,079,963**

The notes on pages 25 to 69 form part of these financial statements.

MARS PET SERVICES UK LIMITED

CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE PERIOD ENDED 28 DECEMBER 2024

	28 December 2024 £000	*31 December 2023* £000
Cash flows from operating activities		
Loss for the financial period	**(457,117)**	*(422,358)*
Adjustments for:		
Depreciation, amortisation, and impairment charges	**421,166**	*432,129*
Loss on disposal of tangible assets	**-**	*808*
Interest paid	**50,045**	*56,426*
Interest received	**(5,676)**	*(419)*
Taxation charge	**(5,890)**	*18,755*
(Increase) in stocks	**(129)**	*(3,638)*
(Increase) in debtors	**(7,310)**	*(37,158)*
Increase in creditors	**81,789**	*168,687*
(Decrease) in provisions	**(472)**	*(13,733)*
Share of operating (loss) in associates	**(39)**	*(18)*
Corporation tax (paid)	**(7,685)**	*(10,209)*
(Increase)/decrease in other non current assets	**-**	*11,630*
Other non-cash items	**-**	*36,870*
Net cash generated from operating activities	**68,682**	*237,772*
Cash flows from investing activities		
Purchase of intangible fixed assets	**(1,855)**	*(2,281)*
Purchase of tangible fixed assets	**(50,193)**	*(68,348)*
Sale of tangible fixed assets	**2,365**	*4,831*
Purchase of unlisted and other investments	**(2,153)**	-
Purchase of fixed asset investments	**(243,097)**	*(326,663)*
Sale of fixed asset investments	**(2,906)**	-
Interest received	**5,676**	*419*
Dividends received	**-**	*94*
Net cash from investing activities	**(292,163)**	*(391,948)*

MARS PET SERVICES UK LIMITED

CONSOLIDATED STATEMENT OF CASH FLOWS (CONTINUED)
FOR THE PERIOD ENDED 28 DECEMBER 2024

Cash flows from financing activities		
New secured loans	**337**	*49*
Repayment of loans	**(530)**	*(592)*
Other new loans	**367,896**	*202,330*
Repayment of other loans	**(99,691)**	*3,427*
Repayment of/new finance leases	**(279)**	*(449)*
Non-controlling interest dividends paid	**(530)**	*(4,390)*
Interest paid	**(26,833)**	*(1,022)*
Advance on long term incentive plan	**(10,474)**	*(5,707)*
Net cash used in financing activities	**229,896**	*193,646*
Net increase in cash and cash equivalents	**6,415**	*39,470*
Cash and cash equivalents at beginning of period	**164,507**	*133,288*
Foreign exchange gains and losses	**(12,145)**	*(8,251)*
Cash and cash equivalents at the end of the period	**158,777**	*164,507*
Cash and cash equivalents at the end of the period comprise:		
Cash at bank and in hand	**158,777**	*164,507*
	158,777	*164,507*

NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 28 DECEMBER 2024

1. General information

The Company is a private company limited by share capital, incorporated in the United Kingdom under the Companies Act 2006 and registered in England and Wales. The address of its registered office is provided on the Company Information page.

2. Summary of significant accounting policies

The principal accounting policies applied in the preparation of these financial statements are set out below and have been applied consistently, other than where new accounting policies have been adopted.

2.1 Statement of compliance

The financial statements have been prepared in accordance with Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

2.2 Cash flow exemption

The Company has not presented a cash flow statement on the grounds that the Company's cash flows are included in the financial statements of the Group.

2.3 Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The Company has taken advantage of the exemption allowed under section 408 of the Companies Act 2006 and has not presented its own Income Statement in these financial statements.

2.4 Basis of consolidation

The financial statements have been prepared on a going concern basis under the historical cost convention and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and the Companies Act 2006 as modified by recognition of certain financial assets and liabilities measured at fair value.

The results represent the 52 week period ended 28 December 2024 and the comparatives represent the 52 week period ended 31 December 2023.

A subsidiary is an entity controlled by the Company. Control is achieved where the Company has the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities.

The results of subsidiaries acquired or disposed of during the period are included in the Income Statement from the effective date of acquisition or up to the effective date of disposal, as appropriate. Where necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with those used by the Group.

Docusign Envelope ID: 1890463A-7409-41D6-949B-06B8014673BF

2.4 Basis of consolidation (continued)

The purchase method of accounting is used to account for business combinations that result in the acquisition of subsidiaries by the Group. The cost of a business combination is measured as the fair value of the assets given, equity instruments issued and liabilities incurred or assumed at the date of exchange, plus costs directly attributable to the business combination. Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at their fair values at the acquisition date. Any excess of the cost of the business combination over the acquirer's interest in the net fair value of the identifiable assets, liabilities and contingent liabilities recognised is recorded as goodwill.

Inter-company transactions, balances and unrealised gains on transactions between the Company and its subsidiaries, which are related parties, are eliminated in full.

Intra-group losses are also eliminated but may indicate an impairment that requires recognition in the consolidated financial statements.

Docusign Envelope ID: 1890463A-7409-41D6-949B-06B8014673BF

2. Summary of significant accounting policies (continued)

2.4 Basis of consolidation (continued)

Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group. Non-controlling interests in the net assets of consolidated subsidiaries are identified separately from the Group's equity therein. Non-controlling interests consist of the amount of those interests at the date of the original business combination and the non-controlling shareholders' share of changes in equity since the date of the combination.

2.5 Company loss

As permitted by section 408 of the Companies Act 2006, the Company's statement of comprehensive income has not been included in these financial statements.

2.6 Going concern

The Group's business activities, together with the factors likely to affect its future development, performance and position are set out on page 2-4. The financial position of the Group, its cash flows, liquidity position and borrowing facilities are described on pages 15-24. In addition, the notes to the financial statements include the Group's objectives, policies and processes for managing its capital; its financial risk management objectives; details of its financial instruments and hedging activities; and its exposures to credit risk and liquidity risk.

The Group meets its day-to-day working capital requirements through free cash and its acquisition requirements through a loan facility from a connected company and has received a letter of support from its ultimate parent company. The Group's forecasts and projections, covering a period of at least 12 months from the approval of these financial statements, show that the Group should be able to operate within the level of its current debt facilities. The Group has plans to continue establishing the foundations of robust veterinary network via improving operating model, harmonising the systems in place, and investing in our Associates to retain the talents in the business. The Group is also working on optimizing customer experience and improving price strategy to accelerate organic growth.

Management has also considered current political instability in Europe and concluded that we do not expect substantial impact on business ability to operate due to business being setup across different countries.
The directors have undertaken a detailed impairment review under the requirements of FRS 102 and have considered a range of possible scenarios over long term revenue and profitability. Based on these scenarios and given the limited track record of the businesses the directors have recorded an impairment charge of £1,261,000,000 to investments within the company financial statements. The impairment charge is mainly driven by an increase of investments from parent company to fund the acquisition investments till the end of 2024 and negative forex effect, and as such is considered, by directors, not to be a significant risk to the going concern of the group.

In considering going concern, the directors have reviewed the cash flow requirements of the Group and Company, both under normal circumstances and reflecting the current assessment of the severe but plausible downside scenarios.

Docusign Envelope ID: 1890463A-7409-41D6-949B-06B8014673BF

2. Summary of significant accounting policies (continued)

2.7 Critical accounting judgements and key sources of estimation uncertainty

In the application of the Group's accounting policies, the directors are required to make judgements (other than those involving estimations) that have a significant impact on the amounts recognised and to make estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

The following are the critical judgements, apart from those involving estimations (which are dealt with separately below), that the directors have made in the process of applying the Group's accounting policies and that have the most significant effect on the amounts recognised in the financial statements.

Recognition of investments as investments, investments in associates and investment in subsidiaries

Investments are recognised in line with the ability of the Group to influence decision making in the respective investee company. Where, in the opinion of the directors, the Group is unable to exert any influence on decision making within the investee company, such investments are recognised as ordinary investments. Where, in the opinion of the directors, the Group is able to influence decision making, but not control decision making within the investee company, such investments are recognised as investments in associates. Where, in the opinion of the directors, the Group is able to exert control over the decision making of the investee company, such investments are recognised as investments in subsidiaries.

2. Summary of significant accounting policies (continued)

2.7 Critical accounting judgements and key sources of estimation uncertainty (continued)

Impairment of investments

The directors have undertaken a detailed impairment review under the requirements of FRS 102 using the discounted cash flow and income approach and have considered a possible scenario over long term revenue and profitability. Based on Management expectations and given the limited track record of the businesses the directors have recorded an impairment charge of £1,261,000,000 to investments within the company financial statements. The evaluation is based on detailed forecasted revenue growth over a period of 10 years reflecting the fact that the business is growing quickly and not in the maturity stage yet, long term growth (LTGR) assumptions beyond the business plan of 2% as per independent industry research and a discount rate, factoring in risk factors, of 9% for Linnaeus Veterinary Limited and 9.5% for AniCura TC AB.

The assumptions of LTGR, discount rate, short-term and steady state EBITDA are judgmental because of the early-stage nature of the industry and reflects management's best estimate based on the available information and strategic plans of the business. The Company applied a hypothetical sensitivity analysis by increasing discount rate by 0.5% which would increase impairment to £1,397,000,000 and decreasing long-term growth rate to 0.5% which would increase the impairment charge to £1,358,000,000. If short-term EBITDA for the next 4 years will be 2.5% lower than planned, the impairment charge would increase to £1,362,000,000. If we increase steady state EBITDA, which is a target margin when business reaches stable stage of development, by 2.5% in each business, the impairment charge would decrease to £982,000,000. The impact of these parameters changes on the impairment is outlined below:

. **Impairment Sensitivity Analysis**

	AniCura £'000	Linnaeus £'000	Total £'000
Base impairment	(793,000)	(468,000)	(1,261,000)
Discount rate			
Increase of 0.5%	(915,000)	(482,000)	(1,397,000)
Decrease of 0.5%	(653,000)	(452,000)	(1,105,000)
Long term growth rate			
Increase of 0.5%	(692,000)	(459,000)	(1,151,000)
Decrease of 0.5%	(882,000)	(476,000)	(1,358,000)
Short - term EBITDA			
Increase of 2.5%	(708,000)	(453,000)	(1,161,000)
Decrease of 2.5%	(879,000)	(483,000)	(1,362,000)
Steady state EBITDA			
Increase of 2.5%	(563,000)	(419,000)	(982,000)
Decrease of 2.5%	(1,024,000)	(517,000)	(1,541,000)

There is no reasonably plausible downside that would lead to an impairment of goodwill.

Docusign Envelope ID: 1890463A-7409-41D6-949B-06B8014673BF

2. Summary of significant accounting policies (continued)

2.7 Critical accounting judgements and key sources of estimation uncertainty (continued)

Accounting for earn out arrangements

Earn out arrangements are accounted for in line with the substance of the arrangement. Where there is a provision for continued employment of a seller, judgement can be required to determine whether the arrangement is accounted for as contingent consideration or employee compensation. Management assesses each sale and purchase agreement to identify the key provisions, understand the requirements and confirm the correct accounting treatment, Where the calculation is based on forecast performance management will recalculate the earn out at period end based on actuals.

Impairment trigger assessment

Section 27 of FRS 102 requires that an annual impairment trigger assessment is performed for each individual asset, or, where that asset does not generate independent cashflows, the Cash Generating Unit to which it belongs. Management performs checks against a range of external and internal indicators and determines whether or not there is a trigger. In respect of Investments held in the Company, judgment is required when considering these indicators. Please see Note 13 for further information.

Key sources of estimation uncertainty

There are no estimates which meet the definition of a key source of estimation uncertainty being, key assumptions concerning the future, and other key sources of estimation uncertainty at the balance sheet date, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial period.

2.8 Revenue recognition

All revenue is measured at the fair value of the consideration received or receivable and represents the amount receivable for goods supplied or services rendered, net of returns, discounts and rebates and value added taxes., sold in the ordinary course of business.
Sale of goods – Revenue from the sale of goods is recognised at the point of sale when the significant risks and rewards of ownership of the goods have been transferred to the customer.
Rendering of services – Revenue from services is recognised when a veterinary consultation, a veterinary procedure or a cremation is completed, and the services is delivered. In most instances the service is performed at a point in time and the revenue can be recognised at the point the service is provided.
Pet Plans – Revenue from pet plans is recognised over the period of the agreement. Revenue is measured as the fair value of the consideration received or receivable..

2.9 Other operating income

Other operating income mainly comprises rental income and is recognised on an accrual basis in accordance with the substance of the relevant agreement.

2.10 Interest income

Interest income is recognised in profit or loss using the effective interest method.

2.11 Exceptional Costs

Exceptional costs are considered to be significant in both nature and quantum and are considered to be non-recurring, details of which have been included in note 4.

2. Summary of significant accounting policies (continued)

2.12 Foreign currency translation

Functional and presentation currency

The Company's functional currency is United States Dollar (USD). This differs from the presentational currency which is Great British Pound (GBP).

Transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rates prevailing on the initial transaction dates.

The financial statements of overseas subsidiary undertakings are translated at the rate ruling at the balances sheet date. The exchange differences arising on the retranslation of opening net assets is taken to other comprehensive income. All other translation differences are taken to the profit and loss account with the exception of differences on foreign currency borrowings to the extent that they are used to finance or provide a hedge against Group equity investments in foreign enterprises, which are taken to other comprehensive income together with the exchange difference on the net investment in these enterprises. Tax charges and credits attributable to exchange differences on those borrowings are also taken to other comprehensive income.

Items recognised directly in equity such as share issues, share premium or repurchases of shares are translated at the historical rate. Differences arising from translation of equity items are recognised directly in equity.

2.13 Business combinations

Business combinations are accounted for by applying the purchase method. The cost of a business combination is the fair value of the consideration given, liabilities incurred or assumed and of equity instruments issued plus the costs directly attributable to the business combination. Where control is achieved in stages the cost is the consideration at the date of each transaction.

Contingent consideration is initially recognised at estimated amount where the consideration is probable and can be measured reliably. Where (i) the contingent consideration is not considered probable or cannot be reliably measured but subsequently becomes probable and measurable or (ii) contingent consideration previously measured is adjusted, the amounts are recognised as an adjustment to the cost of the business combination.

On acquisition of a business, fair values are attributed to the identifiable assets, liabilities and contingent liabilities unless the fair value cannot be measured reliably, in which case the value is incorporated in goodwill. Intangible assets are only recognised separately from goodwill where they are separable and arise from contractual or other legal rights. Where the fair value of contingent liabilities cannot be reliably measured they are disclosed on the same basis as other contingent liabilities.

2. Summary of significant accounting policies (continued)

2.14 Intangible assets

Goodwill arises on business acquisitions and represents the excess of the cost of the acquisition over the Company's interest in the net amount of the identifiable assets, liabilities and contingent liabilities of the acquired business.

Goodwill amortisation is charged on a straight-line basis so as to write off the cost of the asset, less its residual value assumed to be zero, over its useful economic life. Purchased goodwill and goodwill attributable to the acquisition of subsidiaries is being written off over a period of 10 years being the period in which the Group expect to receive benefits from goodwill.

Other intangibles amortisation is charged on a straight-line basis to administrative expenses so as to write off the cost of the asset, less its residual value assumed to be zero, over its useful economic life of between 3 and 10 years being the period in which the Group expect to receive benefit from other intangible assets.

2.15 Intangible assets

Goodwill

Goodwill represents the difference between amounts paid on the cost of a business combination and the acquirer's interest in the fair value of the Group's share of its identifiable assets and liabilities of the acquiree at the date of acquisition. Subsequent to initial recognition, goodwill is measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is amortised on a straight-line basis to the Consolidated Income Statement over its useful economic life.

Other intangible assets

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed 10 years.

2.16 Tangible fixed assets

Tangible fixed assets are carried at cost less accumulated depreciation and accumulated impairment losses.

Depreciation on assets is calculated so as to write off the cost of an asset, less its residual value, over their estimated useful lives.

Depreciation is provided on the following basis:

Land & Buildings - Freehold cost	- Between 0% and 7% of cost
Fixtures, fittings & equipment	- 15% reducing balance or between 10% and 33% of cost
Motor vehicles	- 15% reducing balance

No depreciation is provided on certain freehold land and buildings, as it is the company's policy to maintain these assets so that they keep their previously assessed standard of performance. As the useful economic lives of these assets are of such length and residual values are such that they are not materially different from the carrying amount, any depreciation would not be material. Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

2.17 Investment in subsidiaries

Investments in subsidiaries arise when an investment in the investee results in control over the investee resting with the company. Investments in subsidiaries are held at cost less any subsequent impairment losses.

Docusign Envelope ID: 1890463A-7409-41D6-949B-06B8014673BF

2. Summary of significant accounting policies (continued)

2.18 Investment in associates

Investments in associates arise when an investment in an investee does not result in control of the investee resting with the company. Investments in associates are recognised initially in the consolidated statement of financial position at the transaction price and subsequently adjusted to reflect the group's share of total comprehensive income and equity of the associate, less any impairment.

2.19 Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.
As part of a group recapitalisation the company issued shares and increased its investment in subsidiaries. The company and group repaid existing loans and entered into a new term loan and debt facilities. No cash moved as a result of these transactions and as such no cash movements are shown in the Consolidated Statement of Cash Flows.

2.20 Stocks

Stocks are stated at the lower of cost and net realisable value.

Cost is determined on the first-in, first-out (FIFO) method. Cost includes the purchase price, including taxes, duties, transport and handling directly attributable to bringing the inventory to its present location and condition.

Stocks are also assessed for impairment at each reporting date. The carrying amount of each item of inventory, or Group of similar items, is compared with its selling price less costs to complete and sell. If an item is found to be impaired, its carrying amount is reduced to selling price less costs to complete and sell, and an impairment loss recognised immediately in profit or loss.

2.21 Leases

Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to profit or loss on a straight-line basis over the term of the lease. Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee.

Assets held under finance leases are recognised at the lower of their fair value at inception of the lease and the present value of the minimum lease payments. These assets are depreciated on a straight-line basis over the shorter of the useful life of the asset and the lease term. The corresponding liability to the lessor is included in the Balance Sheet as a finance lease obligation.

Lease payments are apportioned between finance costs in the Income Statement and reduction of the lease obligation so as to achieve a constant periodic rate of interest on the remaining balance of the liability.

2.22 Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the Income Statement over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the Group has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

2. Summary of significant accounting policies (continued)

2.23 Provisions

Provisions are recognised when an event has taken place that gives rise to a legal or constructive obligation, a transfer of economic benefits is probable and a reliable estimate can be made.

Provisions are measured as the best estimate of the amount required to settle the obligation, taking into account the related risks and uncertainties.

Increases in provisions are generally charged as an expense to profit or loss.

2.24 Long-term incentives plans

Long-term incentive plans are recognised as cash-settled when a scheme is either settled in cash or the Group has at its sole discretion the option to settle the obligation in cash and, in the opinion of the directors, will exercise that discretion. The Group's long-term incentive plan consists of convertible instruments issued to certain employees, see note 26.

Cash-settled schemes are initially and subsequently, at each balance sheet date, measured at fair value. The Group recognises a liability based on these fair values taking into account the number of notes that will actually vest and the current proportion of the vesting period. Changes in the value of this liability are recognised in the Income Statement as an expense in the period.

2.25 Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in the Income Statement except that a charge attributable to an item of income and expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Group operates and generates taxable income.

Deferred tax is recognised on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements and on unused tax losses or tax credits in the Group. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.

The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.

2.26 Share Capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

2. Summary of significant accounting policies (continued)

2.27 Defined contribution pension obligation

Defined contribution pension plan

The Group operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Group pays fixed contributions into a separate entity. Once the contributions have been paid the Group has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance Sheet. The assets of the plan are held separately from the Group in independently administered funds.

2.28 Financial instruments

Classification

Financial instruments are classified and accounted for according to the substance of the contractual arrangement, as financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities. Where shares are issued, any component that creates a financial liability of the Company is presented as a liability on the balance sheet. The corresponding dividends relating to the liability component are charged as interest expenses in the profit and loss account.

Financial instruments are classified, recognised and measured in terms of FRS 102 section 11 for basic financial instruments and section 12 for more complex financial instruments. For basic financial instruments, only section 11 will apply whereas section 11 and 12 will apply for the more complex financial instruments and transactions.

Recognition and measurement

All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial assets or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Financial assets and liabilities are only offset in the balance sheet when, and only when there exists a legally enforceable right to set off the recognised amounts and the Group intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

2.29 Trade Debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. All trade debtors are repayable within one year and hence are included at the undiscounted cost of cash expected to be received. A provision for the impairment of trade debtors is established when there is objective evidence that the Group will not be able to collect all amounts due according to the original terms of the debtors.

2. Summary of significant accounting policies (continued)

2.30 Trade Creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Trade creditors are classified as current liabilities if the Group does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and all are repayable within one year and hence are included at the undiscounted amount of cash expected to be paid.

2.31 Impairment

Assets, other than those measured at fair value, are assessed for indicators of impairment at each balance sheet date. If there is objective evidence of impairment, and impairment loss is recognised in profit or loss as described below.

A non-financial asset is impaired where there is objective evidence that, as a result of one or more events that occurred after initial recognition, the estimated recoverable value of the asset has been reduced. The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use.

Any impairment loss in respect of a CGU is allocated first to the goodwill attached to that CGU, and then to other assets within that CGU on a pro-rata basis.

Where indicators exist for a decrease in impairment loss, the prior impairment loss is tested to determine reversal. An impairment loss is reversed on an individual impaired asset to the extent that the revised recoverable value does not lead to a revised carrying amount higher than the carrying value had no impairment been recognised. Where a reversal of impairment occurs in respect of a CGU, the reversal is applied first to the assets (other than goodwill) of the CGU on a pro-rata basis and then to any goodwill allocated to that CGU.

For financial assets carried at amortised cost, the amount of an impairment is the difference between the asset's carrying amount and the best estimate of the amount that would be received for the asset if it were to be sold at the reporting date.

Where indicators exist for a decrease in impairment loss, and the decrease can be related objectively to an event occurring after the impairment was recognised, the prior impairment loss is tested to determine reversal. An impairment loss is reversed on an individual impaired financial asset to the extent that the revised recoverable value does not lead to a revised carrying amount higher than the carrying value had no impairment been recognised.

2.32 Impairment of fixed assets and goodwill

Assets that are subject to depreciation or amortisation are assessed at each balance sheet date to determine whether there is any indication that the assets are impaired. Where there is any indication that an asset may be impaired, the carrying value of the asset (or cash-generating unit to which the asset has been allocated) is tested for impairment. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's (or CGU's) fair value less costs to sell and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (CGUs). Non-financial assets that have been previously impaired are reviewed at each balance sheet date to assess whether there is any indication that the impairment losses recognised in prior periods may no longer exist or may have decreased.

2. Summary of significant accounting policies (continued)

2.33 Associates and joint ventures

An entity is treated as a joint venture where the Group is a party to a contractual agreement with one or more parties from outside the Group to undertake an economic activity that is subject to joint control.

An entity is treated as an associated undertaking where the Group exercises significant influence in that it has the power to participate in the operating and financial policy decisions.

In the consolidated financial statements, interests in associated undertakings are accounted for using the equity method of accounting. Under this method an equity investment is initially recognised at the transaction price (including transaction costs) and is subsequently adjusted to reflect the investors share of the profit or loss, other comprehensive income and equity of the associate. The Consolidated Income Statement includes the Group's share of the operating results, interest, pre-tax results and attributable taxation of such undertakings applying accounting policies consistent with those of the Group. In the Consolidated Balance Sheet, the interests in associated undertakings are shown as the Group's share of the identifiable net assets, including any unamortised premium paid on acquisition.

Any premium on acquisition is dealt with in accordance with the goodwill policy.

2.34 Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.

3. Turnover

	2024	*2023*
	£000	*£000*
Services	**1,084,278**	*1,064,473*
Sales of Goods	**244,654**	*217,320*
	1,328,932	*1,281,793*

	2024	*2023*
	£000	*£000*
United Kingdom	**434,959**	*397,431*
Sweden	**105,049**	*106,805*
Netherlands	**102,211**	*101,282*
Germany	**231,677**	*225,933*
Rest of Europe	**455,036**	*450,342*
	1,328,932	*1,281,793*

4. Exceptional items

	28 December 2024	*31 December 2023*
	£000	*£000*
Non-recurring external expenses	**17,057**	*12,770*
	17,057	*12,770*

Non-recurring external expenses in this period and the prior period include of for two operational restructures a and legal entity simplification project across the group, these costs do not meet the criteria for capitalisation and consist mainly of consultant fees which are considered fully deductible for tax purposes. The costs are considered to not meet the criteria for capitalisation on the basis that these costs are not directly part of the implementation process but would not have been incurred had the implementation not taken place. The impact on tax is a reduction in tax of £4,621,000 (2023: £497,000).

5. Operating loss

The operating loss is stated after charging:

	2024	*2023*
	£000	*£000*
Amortisation of goodwill and other intangibles (Note 11)	**370,457**	*391,655*
Depreciation (Note 12)	**46,160**	*42,707*
Operating leases - property	**52,015**	*48,465*
Operating leases - rentals	**4,654**	*4,234*
Loss on sale of fixed assets	**1,788**	*597*
Impairment	**6,842**	-
Bad debts written off	**1,140**	*1,134*

NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 28 DECEMBER 2024

6. Auditors' remuneration

	28 December 2024	*31 December 2023*
	£000	*£000*
Fees payable to the company's auditors and their associates for the audit of the parent company and the group's consolidated financial statements	**265**	*253*
	265	*253*
Fees payable to the company's auditors and their associates for other services:		
Audit of the company's subsidiaries	**2,603**	*2,916*
Tax advisory services	**105**	*-*
Tax compliance services	**3,411**	*2,044*
Other services	**240**	*489*
Total amount payable to the company's auditors and their associates	**6,624**	*5,702*

Auditors' remuneration for both audit and non-audit services in respect of the Company are borne by its trading subsidiaries.

NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 28 DECEMBER 2024

7. Staff costs

The aggregate employee benefit expenses were as follows:

	Group 28 December 2024 £000	*Group 31 December 2023 £000*
Wages and salaries	**564,619**	*542,543*
Social security costs	**91,025**	*89,689*
Other pension costs	**21,625**	*6,202*
	677,269	*638,434*

The above disclosure excludes 86 (2023: 48) employees of the Company for which costs are recharged in full to another company in the wider "Mars" group".

The average monthly number of employees, including the directors, during the period was as follows:

	2024 No.	*2023 No.*
Vets	**4,837**	*4,521*
Nurses and support staff	**10,850**	*10,515*
	15,687	*15,036*

The Company has no employees other than the directors, who did not receive any remuneration *(2023 - £NIL)*

8. Directors' remuneration

The directors are also officers of another group company and are remunerated by this company which resides outside of this reporting Group, this is consistent with the prior period. It is not practicable to allocate their remuneration between their services as director of this Group and as officers of other Mars group companies.

NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 28 DECEMBER 2024

9. Interest payable and similar expenses

	2024 £000	*2023 £000*
Bank interest payable	**250**	*197*
Other loan interest payable	**47,782**	*55,444*
Finance leases and hire purchase contracts	**2,013**	*878*
	50,045	*56,519*

The other loan interest above is owed to group companies outside of this group and part of the wider Mars group.

10. Taxation

	2024 £000	*2023 £000*
Corporation tax		
Current tax on profits for the period	**-**	*5,733*
	-	*5,733*
Foreign tax		
Foreign tax on income for the period	**4,845**	*15,090*
	4,845	*15,090*
Total current tax	**4,845**	*20,823*
Deferred tax		
Origination and reversal of timing differences	**(10,739)**	*(2,070)*
Total deferred tax	**(10,739)**	*(2,070)*
Tax on loss	**(5,894)**	*18,753*

10. Taxation (continued)

Factors affecting tax charge for the period

The tax assessed for the period is higher *(2023 - higher than)* the standard rate of corporation tax in the UK of 25% *(2023 - 23.5%)*. The differences are explained below:

	2024 £000	*2023* *£000*
Loss on ordinary activities before tax	**(463,011)**	*(403,604)*
Loss on ordinary activities multiplied by standard rate of corporation tax in the UK of 25% (2023 - 23.5%)	**(115,693)**	*(94,847)*
Effects of:		
Non-tax deductible expenses	**116,308**	*106,053*
Other timing differences - UK	**(5,271)**	*(2,571)*
Overseas timing differences	**(2,298)**	*(4,048)*
Difference on overseas tax rates	**(96)**	*1,855*
Adjustments for previous period	**-**	*544*
Difference current tax and deferred tax from previous period	**(8,589)**	*12,725*
Unrealised tax losses carried forward	**-**	*(958)*
Valuation allowance	**9,745**	*-*
Total tax charge for the period	**(5,894)**	*18,753*

11. Intangible assets

Group and Company

	Other intangibles £000	Goodwill £000	Total £000
Cost			
At 1 January 2024	**17,574**	**3,748,559**	**3,766,133**
Additions	**1,855**	**230,293**	**232,148**
Disposals	**(16)**	**-**	**(16)**
Foreign exchange movement	**(1,379)**	**(153,613)**	**(154,992)**
At 28 December 2024	**18,034**	**3,825,239**	**3,843,273**
Amortisation			
At 1 January 2024	**9,348**	**2,192,723**	**2,202,071**
Charge for the period on owned assets	**2,622**	**367,835**	**370,457**
On disposals	**(23)**	**-**	**(23)**
Foreign exchange movement	**(809)**	**(90,385)**	**(91,194)**
At 28 December 2024	**11,138**	**2,470,173**	**2,481,311**
Net book value			
At 28 December 2024	**6,896**	**1,355,066**	**1,361,962**
At 31 December 2023	*8,226*	*1,555,836*	*1,564,062*

11. Intangible assets (continued)

All of the goodwill in 2024 (2023: 100%) is as a result of business combinations and have arisen due to the difference between the carrying value of the net assets acquired and the purchase price. Goodwill consists of intangible items such as local market positions, business development potential and synergies, future earning capacity and customer relationships. The directors have considered the accounting requirements of FRS102 and have concluded that there were no other material intangible assets acquired with the above businesses.
As required by FRS 102, the directors have performed an impairment trigger assessment including consideration of external factors such as adverse changes in the market, CMA investigation in the UK and its impact on customers' behaviour, and internal indicators such as a comparison of actual performance to the forecast and material one-offs following the closure of large hospital for several periods. Management highlighted that 2024 performance is better vs 2023 from revenue perspective, however one-off factors and overall market situation has led to lower earnings vs 2023. The business results were also below plan, therefore, full impairment review was performed. Enterprise fair value is significantly higher vs Goodwill book value and as such no impairment was recorded.

All subsidiaries acquired during the period primarily provide veterinary care and or veterinary hospital care and trade primarily in the country of their incorporation.

During the period, AniCura TC AB, a subsidiary of the company, through various of its own subsidiary companies across Europe, acquired 100% of the issued share capital of fifteen companies, obtaining control. None of these acquisitions are considered, by the directors, to be individually material to the group. Please refer to the list of subsidiaries in note 31 for details of these companies.

The companies contributed £11,578,000 of revenue and £837,000 of profit to the Group's loss for the period between the date of acquisition and the balance sheet date.

The amounts recognised in respect of the identifiable assets acquired and liabilities assumed are as set out in the table below. All acquisition balances represents the value of acquisitions at the date of signing the Financial Statements.

	28 December 2024 £000
Assets and liabilities acquired	
Financial assets	**8,179**
Stocks	**1,201**
Tangible assets	**3,672**
Financial liabilities	**(3,419)**
Total identifiable assets	**9,633**
Goodwill	**171,397**
	181,030

11. Intangible assets (continued)

Satisfied by:	
Cash	**137,468**
Deferred consideration	**(6,706)**
Contingent consideration	**50,260**
Acquisition costs	**8**
	181,030

Cash consideration	**133,311**
Less: cash and cash equivalent balances acquired	**(2,257)**
	131,054

11. Intangible assets (continued)

During the period, Linnaeus Veterinary Limited, a subsidiary of the company, acquired 100% of the issued share capital of one company, obtaining control as well as the trade and assets of one company. None of these acquisitions is considered by the directors to be individually material to the group. Please refer to the list of subsidiaries in note 31 for details of these companies.

The companies contributed £3,078,998 of revenue and £558,728 of profit to the Group's loss for the period between The date of acquisition and the balance sheet date.

The amounts recognised in respect of the identifiable assets acquired and liabilities assumed are as set out in the table below. All acquisition balances represent the value of acquisitions at the date of signing the Financial Statements.

	28 December 2024 £000
Assets and liabilities acquired	
Financial assets	***5,861***
Stocks	***451***
Tangible assets	***2,632***
Financial liabilities	***(5,727)***
Total identifiable assets	***3,217***
Goodwill	***59,144***
	62,361
Cash	***50,718***
Deferred consideration	***11,643***
	62,361
Cash analysis	
Cash consideration	***54,811***
Less: cash and cash equivalent balances acquired	***(4,122)***
	50,689

12. Tangible assets

Group

	Land and buildings £000	Fixtures, fittings & equipment £000	Motor vehicles £000	Total £000
Cost or valuation				
At 1 January 2024	**213,128**	**206,490**	**1,445**	**421,063**
Additions	**25,813**	**30,282**	**402**	**56,497**
Disposals	**(1,529)**	**(6,373)**	**(31)**	**(7,933)**
Transfers between classes	**459**	**(459)**	**-**	**-**
Exchange adjustments	**(9,543)**	**(9,907)**	**(51)**	**(19,501)**
At 28 December 2024	**228,328**	**220,033**	**1,765**	**450,126**
Depreciation				
At 1 January 2024	**48,773**	**97,906**	**1,079**	**147,758**
Charge for the period on owned assets	**16,368**	**29,541**	**251**	**46,160**
Disposals	**(617)**	**(5,296)**	**27**	**(5,886)**
Impairment charge	**3,196**	**1,355**	**-**	**4,551**
Exchange adjustments	**(1,894)**	**(8,098)**	**(105)**	**(10,097)**
At 28 December 2024	**65,826**	**115,408**	**1,252**	**182,486**
Net book value				
At 28 December 2024	**162,502**	**104,625**	**513**	**267,640**
At 31 December 2023	*164,355*	*108,584*	*366*	*273,305*

12. Tangible assets (continued)

The net book value of land and buildings may be further analysed as follows:

	28 December 2024 £000	*31 December 2023 £000*
Long leasehold	**162,502**	*168,168*
	162,502	*168,168*

13. Investments

Group

	Investments in associate companies £000
Cost or valuation	
At 1 January 2024	**7**
Additions	**2,154**
At 28 December 2024	**2,161**
Net book value	
At 28 December 2024	**2,161**
At 31 December 2023	*7*

13. Investments (continued)

Company

	Investments in subsidiary companies £000
Cost or valuation	
At 1 January 2024	**4,388,588**
Additions	**167,173**
Foreign exchange movement	**38,105**
At 28 December 2024	**4,593,866**
Impairment	
At 1 January 2024	**1,369,000**
Charge for the period	**1,261,000**
At 28 December 2024	**2,630,000**
Net book value	
At 28 December 2024	**1,963,867**
At 31 December 2023	*3,019,588*

The investment balance represents the Company's investments in each of the two subsidiary trading groups - Linnaeus Veterinary Limited and AniCura TC AB. The directors have undertaken a detailed impairment review under the requirements of FRS 102 and have considered a range of possible scenarios over long term revenue and profitability. Based on these scenarios, the Directors have recorded an impairment charge of £1,261,000,000 to investments within the company financial statements. The impairment charge is mainly driven by general industry slowdown and consequences of Competition and Markets Authority (CMA) process. The Directors do not see this impairment charge as a significant risk to the going concern of the group.

14. Stocks

	Group 28 December 2024 £000	*Group 31 December 2023 £000*
Finished goods and goods for resale	**37,100**	*35,448*

The carrying value of stock at period end approximates its replacement value.

NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 28 DECEMBER 2024

15. Debtors: amounts falling due within one year

	Group 28 December 2024 £000	*Group 31 December 2023 £000*	**Company 28 December 2024 £000**	*Company 31 December 2023 £000*
Trade debtors	**49,495**	*50,682*	-	-
Amounts owed by group undertakings	**21,695**	*3*	**79,106**	*187*
Other debtors	**47,778**	*48,527*	-	-
Prepayments and accrued income	**16,522**	*15,870*	-	-
Tax recoverable	**(121)**	*-*	-	-
Deferred taxation	**39,154**	*39,501*	-	-
	174,523	*154,583*	**79,106**	*187*

Amounts owed by group undertakings represent one loan to subsidiary undertakings. The principal amount, including any rolled up interest charges, is repayable in full on 31 December 2025.

Interest shall accrue daily on the unpaid principal amount at a rate per annum equal to 5.0%. Prior year principal amount was fully repaid in November 2024.

Deferred taxation above is falling due after more than one year.

16. Creditors: Amounts falling due within one year

	Group 28 December 2024 £000	*Group 31 December 2023 £000*	**Company 28 December 2024 £000**	*Company 31 December 2023 £000*
Bank loans and overdrafts	**365**	*705*	-	-
Other loans	**-**	*988*	-	*8,115*
Trade creditors	**32,163**	*47,966*	-	-
Amounts owed to group undertakings	**90,349**	*-*	-	-
Corporation tax	**13,746**	*17,650*	-	-
Other taxation and social security	**32,774**	*35,858*	-	-
HP, finance leases and other lease liabilities	**332**	*185*	-	-
Other creditors	**59,757**	*60,236*	-	-
Accruals and deferred income	**59,748**	*62,818*	-	-
	289,234	*226,406*	-	*8,115*

17. Creditors: Amounts falling due after more than one year

	Group 28 December 2024 £000	*Group 31 December 2023 £000*	Company 28 December 2024 £000	*Company 31 December 2023 £000*
Bank loans and overdrafts	**633**	*383*	**-**	*-*
Other loans	**944,444**	*877,013*	**963,010**	*870,932*
HP, finance leases and other lease liabilities	**(408)**	*-*	**-**	*-*
Other creditors	**138,422**	*117,626*	**-**	*-*
Accruals and deferred income	**-**	*-*	**-**	*20,869*
	1,083,091	*995,022*	**963,010**	*891,801*

18. Loans and borrowings

	Group 28 December 2024 £000	*Group 31 December 2023 £000*	Company 28 December 2024 £000	*Company 31 December 2023 £000*
Amounts falling due within one year				
Bank loans and overdrafts	**365**	*705*	**-**	*-*
Other loans	**-**	*988*	**-**	*8,116*
Finance lease liabilities	**332**	*-*	**-**	*-*
Total	**697**	*1,693*	**-**	*8,116*
Non-current loans and borrowings				
Bank loans and overdrafts	**633**	*383*	**-**	*-*
Other loans	**944,444**	*877,013*	**963,010**	*870,932*
Finance lease liabilities	**(408)**	*-*	**-**	*-*
	944,669	*877,396*	**963,010**	*870,932*
	944,669	877,396	**963,010**	870,932

18. Loans and borrowings (continued)

Group - Other loans

Group other loans are loans owed to connected companies in wider "Mars" group. The loans are repayable between December 2025 and November 2029.
Interest is levied at a commercial rate of between 4.6% to 6.5% per annum, repayable annually in arrears while the capital repayment is due at the end of the loan period. The connected companies comprise Mars, Incorporated.
During the period a new facility was put in place: line of credit with a maximum drawdown of SEK 6,900,000,000 is repayable by 31 December 2025, and interest is payable at 4.57%. Prior period facility of SEK 2,900,000,000 was repaid in full on 14 November 2024.

Group - Bank loans

Bank loans outstanding of £1,028,000 (2023 - £746,000) are repayable between January 2025 and June 2026. Interest is levied at a rate of 1% and 8.11% per annum. These loans are repayable at the end of the loan period, with interest repayments varying from loan to loan. These loans are unsecured.

19. Deferred taxation

Group

	2024 **£000**	*2023* *£000*
At beginning of period	**39,501**	*26,159*
Credited to profit or loss	**(347)**	*13,342*
At end of period	**39,154**	*39,501*

The deferred tax asset is made up as follows:

	Group 28 December 2024 £000	*Group 31 December 2023 £000*
Fixed asset timing differences	**6,994**	*520*
Short term timing differences	**3,240**	*14,200*
Losses and other deductions	**28,920**	*24,781*
	39,154	*39,501*

There is no expiry date on timing differences, unused tax losses or tax credits.

20. Other provisions

Group

	Other £000
At 1 January 2024	**13**
Charged to profit or loss	**(1)**
At 28 December 2024	**12**

21. Share capital

	28 December 2024	*31 December 2023*
	£000	*£000*
Allotted, called up and fully paid		
10 *(2023 - 9)* Ordinary shares of £1.00 each	-	-

On 14 November 2024 the company issued 1 share and received consideration of £2,088,001,204.

22. Reserves

Share premium account

Share premium reserve represents the premium in excess of the par value of share capital received from shareholders.

Profit and loss account

The profit and loss account represents the accumulated profits and losses since incorporation.

23. Analysis of net debt

	Group at 1 January 2024 £000	Cash flows £000	Other non-cash items £000	Foreign exchange movements £000	Group at 28 December 2024 £000
Cash at bank and in hand	**164,524**	**(18,068)**	**-**	**8,198**	**154,654**
Bank overdrafts	**(1,088)**	**194**	**81**	**(184)**	**(997)**
Other loans	**(878,001)**	**(269,188)**	**208,285**	**(5,540)**	**(944,444)**
Finance leases	**(185)**	**33**	**128**	**154**	**130**
	-	**-**	**-**	**-**	**-**
	(714,750)	**(287,029)**	**208,494**	**2,628**	**(790,657)**

24. Pension Schemes

Defined contribution pension scheme

The Group operates a defined contribution pension scheme. The pension cost charge for the period represented contributions payable by the Group to the scheme and amounted to £21,625,000 (2023 - £6,202,000).

Contributions totalling £321,327 (2023 - £383,000) were payable to the scheme at the end of the period and are included in creditors.

25. Long-term incentive plans

During the period, the group had in place long-term incentive plans with certain employees within the group. As part of this scheme, the group issues convertible instruments to participants where each instrument has the ability to be converted into Ordinary and Preference shares such that the fully diluted shares of the company maintain a ratio of 15:85 and/or be called for cash subject to the terms and conditions determined by the group. Under this agreement, 100% of issued instruments will vest 30 months from the issuance date. Under the terms of the agreement, vested instruments will be redeemed at market value while, in the event of a triggering event, unvested instruments will be redeemed at the lower of acquisition cost and market value. Under this agreement, the group has a right, but not an obligation, to call the instruments and settle in cash within 20 days of 1 January 2024 an amount equal to 25% of the instruments respectively with a right to call on and settle in cash, the remaining instruments within 20 days of 1 January 2025. The Company has appointed independent valuers for this scheme and the group has a non-binding intention that this scheme is revalued bi-annually at 30 June and 31 December.

No convertible instruments were issued in the period to 28 December 2024 (2023 - nil). No instruments vested in the period (2023 - nil). However, 716 were forfeited (2023 - 215) in the period and 2,701 were redeemed in the period (2023: 2,130).

26. Commitments under operating leases

At 28 December 2024 the Group and the Company had future minimum lease payments due under non-cancellable operating leases for each of the following periods:

	Group 28 December 2024 £000	*Group 31 December 2023 £000*
Not later than 1 year	**38,959**	*36,825*
Later than 1 year and not later than 5 years	**87,110**	*113,224*
Later than 5 years	**59,795**	*100,938*
	185,864	*250,987*

27. Capital commitments and guarantees

At 28 December 2024 the Group has capital commitments of £4,659,000 (2023: £5,600,000). The Company had no capital commitments (2023: £Nil).

28. Post balance sheet events

There were no post balance sheet events between the balance sheet date and the date of signing.

29. Related party transactions

The company has taken advantage of the exemption available and has not disclosed transactions with the ultimate parent company or any wholly owned subsidiary of the wider Mars group.

It is the opinion of the directors that they, along with those senior members of management responsible for the overall operational and strategic direction of the Group's undertakings within the United Kingdom and Europe are considered to be members of key management. Remuneration of key management in the period totalled £4,232,000 (2023: £3,513,000).

Docusign Envelope ID: 1890463A-7409-41D6-949B-06B8014673BF

30. Parent and ultimate parent undertaking

The parent undertaking is Mars Vet Health International Holding Corp., a company registered in the United States of America. The largest and smallest group in which the results are consolidated is Mars Incorporated and Mars Vet Health International Holding Corp, respectively, both companies registered in the state of Delaware in the United States of America at the following address, 1209 Orange Street, Wilmington, DE, 19801. The ultimate parent and controlling party is Mars Incorporated.

The largest and smallest groups in which these consolidated financial statements are publicly available are these consolidated financial statements, copies of which can be found at Companies House.

MARS PET SERVICES UK LIMITED

NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 28 DECEMBER 2024

31 List of companies (continued)

Subsidiary undertakings	Country of incorporation	Street address of the hospital	City/Town	Postal code	Class of shares held	Proportion of voting rights and shares held current year	Proportion of voting rights and shares held prior year
Mon Veterinari, S.L.U.	Andorra	Carrer Josep Viladomat 36, AD700	Escaldes-Engordany	ad700	Ordinary	100	100
AniCura Austria Holding GmbH	Austria	Breitenseer Strasse 16	Wien	1140	Ordinary	100	100
AniCura Breitensee Service GmbH	Austria	Breitenseer Strasse 16	Wien	1140	Ordinary	-	100
AniCura HB Service GmbH	Austria	Lastenstrasse 2	Hollabrunn	2020	Ordinary	-	100
AniCura KB Dienstleistungs GmbH	Austria	Laaerstrasse 62	Korneuburg	2100	Ordinary	-	100
AniCura maka Service GmbH	Austria	Aspernstrasse 130	Wien	1220	Ordinary	-	100
AniCura Schwanenstadt Service GmbH	Austria	Mühlfeldstrasse 2	Schwanenstadt	4690	Ordinary	-	100
AniCura Gratkorn Service GmbH	Austria	Andreas Leykam-Platz 1	Gratkorn	8101	Ordinary	-	100
AniCura Belgium B.V.	Belgium	Kleine Kloosterstraat 6	Zaventem	1932	Ordinary	100	100
AC Clinico Belgium BV	Belgium	Frans Beirenslaan 155	Borsbeek	2150	Ordinary	100	100
AC Het Binnenhof BV	Belgium	Bisschopslaan 68	Beerse	2340	Ordinary	-	100
AC Malpertuus BV	Belgium	Leenstraat 2a	Destelbergen	9070.	Ordinary	-	100
AC De Ark BV	Belgium	Probastraat 1	Hulshout	2235	Ordinary	-	100
AC Causus BV	Belgium	Verhelstraat 1	Oudenburg	8460	Ordinary	-	100
AC Plantijn B.V	Belgium	Borsbeeksebrug 34	Berchem	2600	Ordinary	-	100
AC De Vliet B.V.	Belgium	Dendermondsesteenweg 74	Puurs	2870	Ordinary	-	100
AC Anthemis B.V	Belgium	De Beughemlaan 34B	Kapelle-op-den-Bos	1880	Ordinary	-	100
AC ADK SRL	Belgium	Rue de la Libération 1	Verviers	4800	Ordinary	-	100
AC Hond en Kat BV	Belgium	Emiel Clauslaan 134	Deinze	9800	Ordinary	-	100
AniCura Herckenrode BV	Belgium	Holrakkerstraat 15	Kuringen	3511	Ordinary	-	100
AC De Molenhoek BV	Belgium	Brakelsesteenweg 323	Ninove	9406	Ordinary	-	100
AC Den Eikbos BV	Belgium	Eikbosweg 99	Zemst	1980	Ordinary	-	100
AC du Chateau SRL	Belgium	Avenue George Bedoret 46	Gembloux	5030	Ordinary	-	100

MARS PET SERVICES UK LIMITED

NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 28 DECEMBER 2024

31 List of companies (continued)

Subsidiary undertakings	Country of incorporation	Street address of the hospital	City/Town	Postal code	Class of shares held	Proportion of voting rights and shares held current year	Proportion of voting rights and shares held prior year
AC Vetimacs SRL	Belgium	Rue Maurice Wilmotte 16	Saint Gilles	1060	Ordinary	-	100
AC VetTeam SRL	Belgium	Esplanade de la Paix 3	Herstal	4040	Ordinary	-	100
AC Carolovet SRL	Belgium	Rue de Gilly 2	Charleroi	6010	Ordinary	-	100
AC Sint-Jan BV	Belgium	Kapelsesteenweg 246	Brasschaat	2930	Ordinary	-	100
AC Vetocambre	Belgium	Louizalaan 176	Brussel	1000	Ordinary	100	-
Regia Vet s.r.o.	Czech Republic	Hráského 2231/25	Prague	148 00	Ordinary	100	-
VETCENTRUM Duchek s.r.o.	Czech Republic	K Hájům 2671/8	Prague	155 00	Ordinary	100	-
Ada's Kæledyrskrematorium ApS	Denmark	Hojvangsvej 15	Hedehusene	2640	Ordinary	100	100
AniCura APS	Denmark	Marielundvej 46 E, st, 2730	Herlev	2730	Ordinary	100	100
Ølby Dyrehospital ApS	Denmark	Ølbycenter 12	Ølby	4600	Ordinary	100	100
AniCura Property Aps	Denmark	Marielundvej 46 E, st, 2730	Herlev	2730	Ordinary	100	100
Himmelev Dyreklinik ApS	Denmark	Byleddet 4	Roskilde	4000	Ordinary	100	-
AniCura Support Services SAS	France	158 Avenue Thiers	Lyon	69006	Ordinary	100	100
Sas Clinique Veterinaire Saint-Roch	France	18 Rue De Dompierre	La Rochelle	17000	Ordinary	-	100
Selarl Zebreasoma	France	3 Rue La Fayette	Strasbourg	67100	Ordinary	-	100
Centre Hospitalier Veterinaire Pommery S.A.S.	France	226 Boulevard Pommery, 51100	Reims	51100	Ordinary	-	100
SCI 226 Pommery (PROPCO)	France	226 Boulevard Pommery, 51100	Reims	51100	Ordinary	100	100
Vetref S.A.S.	France	7 Rue James Watt, 49070	Beaucouzé	49070	Ordinary	-	100
Clinique Vétérinaire Lorrainevet SAS	France	127 rue Pierre-Gilles de Gennes, 54710	Ludres	54710	Ordinary	-	100
SAS Centre Hospitalier Veterinaire Nordvet	France	1 Rue Delesalle	La Madeleine	59110	Ordinary	-	100
SELARL Veterinaire Armonia	France	Rue Serge Mauroit	Villefontaine	38090	Ordinary	-	100/49,999
Centre Hospitalier Vétérinaire Aquivet	France	19 Avenue de la Forêt	EYSINES	33320	Ordinary	-	100/49,972
SA Vétérinaire des Tilleuls	France	3 Rue de l'Innovation	Hoerdt	67720	Ordinary	-	100/39,998
SA Volvestre	France	14 Chemin De l'Industrie	Carbonne	31390	Ordinary	-	100/49,5

MARS PET SERVICES UK LIMITED

NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 28 DECEMBER 2024

31 List of companies (continued)

Subsidiary undertakings	Country of incorporation	Street address of the hospital	City/Town	Postal code	Class of shares held	Proportion of voting rights and shares held current year	Proportion of voting rights and shares held prior year
SELARL Arc-en-Ciel	France	8 rue Jean Moulin	Yutz	57970	Ordinary	-	100/49,99
SELARL Broceliandevet	France	Rue Du Grand Jardin	Saint-Malo	35400	Ordinary	-	100/49,957
SELARL Medicabanis	France	4 Rue de cabanis	L'Union	31240	Ordinary	-	100/49,9975
AniCura SAS	France	75 boulevard Rosselli	Belleville-en-Beaujolai	69220	Ordinary	100/49,998	100/49,9975
SA POLE VETERINAIRE PARISIEN	France	17 boulevard des Filles du Calvaire	Paris	75003	Ordinary	-	100/49,9975
SA Vétérinaires de la Saulx	France	12 AVENUE DU XVEME CORPS	Revigny-sur-Ornain	55800	Ordinary	-	100/49,9975
SEARL Vet 24	France	994 Avenue de la Republique	Marcq-en-Baroeul	59700	Ordinary	-	100/49,9975
Advetia	France	9 Avenue Louis Breguet	Vélizy-Villacoublay	78140	Ordinary	100/49,50	-
Vetetoile	France	1120 Route de Gémenos CENTRE ALTA ROCCA	Aubagne	13400	Ordinary	100/49,90	-
AniCura Tierklinik Egelsbach GmbH	Germany	Boschring 8	Egelsbach	63329	Ordinary	100	100
AniCura Aachen GmbH	Germany	Trierer Str. 652-658	Aachen	52078	Ordinary	-	100
AniCura Bielefeld GmbH	Germany	Bechterdisser Straße 6	Bielefeld	33719	Ordinary	100	100
AniCura Deutschland GmbH	Germany	Marienplatz 61	Ravensburg	88212	Ordinary	100	100
AniCura Germany TC GmbH	Germany	Biberger Straße 18	Unterhaching	82008	Ordinary	100	100
AniCura Gerresheim Fidelios GmbH	Germany	Gräulinger Str. 80	Düsseldorf	40625	Ordinary	100	100
AniCura Kassel GmbH	Germany	Umbachsweg 8	Kassel	34123	Ordinary	100	100
AniCura Kleintierklinik Babenhausen GmbH	Germany	Alpenstraße 27	Babenhausen	87727	Ordinary	100	100
AniCura Kleintierzentrum Weingarten GmbH	Germany	Am Eisweiher 11	Weingarten	76356	Ordinary	-	100
AniCura Kleintierzentrum Reutlingen GmbH	Germany	August-Lämmle-Straße 51	Reutlingen	72766	Ordinary	-	100
AniCura Kleintierspezialisten Augsburg GmbH	Germany	Max-Josef-Metzger-Straße 9	Augsburg	86157	Ordinary	100	100
AniCura Kleintierspezialisten Ravensburg GmbH	Germany	Zuppingerstraße 10/1	Ravensburg	88213	Ordinary	100	100
AniCura Kleintierzentrum Heilbronn GmbH	Germany	Frankfurter Str. 6	Heilbronn	74072	Ordinary	100	100
AniCura Kleintierzentrum Mayen GmbH	Germany	Römerstr. 75	Mayen	56727	Ordinary	100	100

Docusign Envelope ID: 1890463A-7409-41D6-949B-06B8014673BF

31 List of companies (continued)

Subsidiary undertakings	Country of incorporation	Street address of the hospital	City/Town	Postal code	Class of shares held	Proportion of voting rights and shares held current year	Proportion of voting rights and shares held prior year
AniCura Kleintierzentrum Neckarwiesen GmbH	Germany	Fritz-Muller-Strasse 144	Esslingen A.N.	73730	Ordinary	100	100
AniCura Kleintierzentrum Neu-Ulm GmbH	Germany	Leipheimer Straße 9-11	Neu-Ulm	89233	Ordinary	100	100
AniCura Mönchengladbach Venn GmbH	Germany	Beltinghovener Str. 1	Mönchengladbach	41068	Ordinary	100	100
AniCura Tierklinik Neandertal GmbH	Germany	Landstraße 51	Haan	42781	Ordinary	100	100
AniCura Potsdam GmbH	Germany	Am Wildpark 1	Potsdam	14469	Ordinary	100	100
AniCura Preußisch Oldendorf GmbH	Germany	Am Bodenbach 7	Preubisch-Oldendorf	32361	Ordinary	100	100
AniCura Recklinghausen GmbH	Germany	Am Stadion 113	Recklinghausen	45659	Ordinary	-	100
AniCura Bökelberg GmbH	Germany	Krefelder Str. 461	Mönchengladbach	41066	Ordinary	100	100
AniCura Kleintierfachpraxis Haßloch GmbH	Germany	Dr. -Siebenpfeiffer-Str. 13	Haßloch	67454	Ordinary	100	100
AniCura Tierärztliche Spezialisten Hamburg GmbH	Germany	Rodigallee 85	Hamburg	22043	Ordinary	100	100
AniCura Tierklinik Haar GmbH	Germany	Keferloher Str. 25	Haar	85540	Ordinary	100	100
AniCura Trier GmbH	Germany	Pellinger Str. 57	Trier	54294	Ordinary	100	100
AniCura Walluf GmbH	Germany	Am Klingenweg 21	Walluf	65396	Ordinary	-	100
AniCura Witten GmbH	Germany	Am Lockvogel 14C	Witten	58452	Ordinary	100	100
AniCura Online Germany GmbH	Germany	Biberger Str. 18	Unterhaching	82008	Ordinary	100	100
AniCura Stockelsdorf GmbH	Germany	Ahrensböker Str. 74	Stockelsdorf	23617	Ordinary	100	100
Crempet Tierkrematorium GmbH	Germany	Werner-von-Siemens-Str. 6	Laudenbach	69514	Ordinary	100	100
Anicura Wiesloch GmbH	Germany	Ludwig-Wagner-Straße 31	Wiesloch	69168	Ordinary	100	100
Kleintierklinik Bretzenheim GmbH	Germany	In den zehn Morgen 4	Bretzenheim	55559	Ordinary	100	100
AniCura Alzenau GmbH	Germany	Mömbriser Str. 100	Alzenau	63755	Ordinary	-	100
Kleintierorthopädie Wiesbaden GmbH	Germany	Berta-Cramer-Ring 34	Wiesbaden	65205	Ordinary	100	100
Kleintierspezialisten Kempten GmbH	Germany	Bleicherstr. 1	Kempten im Allgäu	87437	Ordinary	100	100
AniCura Kleve GmbH	Germany	Landwehr 8	Kleve	47533	Ordinary	100	100
Tierärztliches Labor Freiburg GmbH	Germany	Engesserstr. 4B	Freiburg im Breisgau	79108	Ordinary	-	100

MARS PET SERVICES UK LIMITED

NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 28 DECEMBER 2024

31 List of companies (continued)

Subsidiary undertakings	Country of incorporation	Street address of the hospital	City/Town	Postal code	Class of shares held	Proportion of voting rights and shares held current year	Proportion of voting rights and shares held prior year
AniCura Tönisvorst GmbH	Germany	Willicher Str. 18	Tönisvorst	47918	Ordinary	100	100
Tiergesundheitszentrum am Bürgerhaus Süd GmbH	Germany	Körnerplatz 10	Recklinghausen	45661	Ordinary	100	100
AniCura Jena GmbH	Germany	Erfurter Str. 50	Jena	07743	Ordinary	-	100
AniCura Tierärztliches Fachzentrum Bamberg GmbH	Germany	Rothofer Weg 40	Bamberg	96049	Ordinary	100	100
Tierkrematorium Schwarzwald GmbH	Germany	Lise-Meitner-Straße 11	Schramberg-Sulgen	78713	Ordinary	100	100
AniCura Ahlen GmbH	Germany	Bunsenstraße 20	Ahlen	59229	Ordinary	100	100
AniCura Benrath GmbH	Germany	Bonner Str. 323	Düsseldorf	40589	Ordinary	-	100
AniCura Bremen-Peterswerder GmbH	Germany	Stader Str. 35	Bremen	28205	Ordinary	-	100
AniCura Borken GmbH	Germany	Fontanestr. 3	Borken	46325	Ordinary	100	100
AniCura Duisburg-Asterlagen GmbH	Germany	Dr.-Detlev-Karsten-Rohwedder-Str. 11	Duisburg	47228	Ordinary	100	100
AniCura Tierklinik Trier GbR	Germany	Pellinger Str. 57	Trier	54294	Ordinary	65	65
AniCura Flensburg GmbH	Germany	Lilienthalstraße 19	Flensburg	24941	Ordinary	100	100
AniCura Schönfließ GmbH	Germany	Am Anger 6	Mühlenbecker Land	16567	Ordinary	100	100
AniCura Trier Hausapotheke GbR	Germany	Pellinger Str. 57	Trier	54294	Ordinary	65	65
AniCura Wahlstedt GmbH	Germany	Wiesenweg 2-8	Wahlstedt	23812	Ordinary	100	100
AniCura Regensburg GmbH	Germany	Hofer Straße 11	Regensburg	93057	Ordinary	100	100
AniCura Kleintierspezialisten Karlsruhe GmbH	Germany	Hoffstraße 6	Karlsruhe	76133	Ordinary	-	100
AniCura Hamburg Niendorf GmbH	Germany	Garstedter Weg 274	Hamburg	22455	Ordinary	100	100
AniCura Quickborn GmbH	Germany	Himmelsmoorchaussee 42	Quickborn	25451	Ordinary	-	100
AniCura Hohenlohe GmbH	Germany	Sonnenstr. 24	Frankenhardt	74586	Ordinary	100	100
AniCura Essen Reuenberg GmbH	Germany	Reuenberg 50A	Essen	45357	Ordinary	100	100
AniCura Bergisch Gladbach GmbH	Germany	Richard-Zanders-Straße 45	Bergisch Gladbach	51469	Ordinary	100	100
AniCura Eschborn GmbH	Germany	Schwalbacher Straße 54	Eschborn	65760	Ordinary	100	100

Docusign Envelope ID: 1890463A-7409-41D6-949B-06B8014673BF

31 List of companies (continued)

Subsidiary undertakings	Country of incorporation	Street address of the hospital	City/Town	Postal code	Class of shares held	Proportion of voting rights and shares held current year	Proportion of voting rights and shares held prior year
AniCura Speyer GmbH	Germany	Tullastraße 9	Speyer	67346	Ordinary	100	100
AniCura Ludwigshafen GmbH	Germany	Silgestr. 1	Ludwigshafen	67067	Ordinary	100	100
AniCura Geldern GmbH	Germany	Am Pannhofen 1-3	Geldern	47608	Ordinary	100	100
AniCura Ingelheim GmbH	Germany	Bahnhofstr. 102	Ingelheim	55218	Ordinary	100	100
AniCura Wiesbaden Schierstein GmbH	Germany	Saarbrücker Allee 7	Wiesbaden	65201	Ordinary	100	100
AniCura Ludwigsburg-Oßweil GmbH	Germany	Karl-Heinrich-Käferle-Str. 2	Ludwigsburg	71640	Ordinary	100	100
AniCura Lörrach GmbH	Germany	Bahnhofstr. 11	Lörrach	79539	Ordinary	100	100
AniCura Hannover GmbH	Germany	Hildesheimer Straße 386	Hannover	30519	Ordinary	100	100
AniCura Bad Dürrheim GmbH	Germany	Aussiedlerhöfe 11	Bad Dürrheim	78073	Ordinary	100	100
AniCura Sankt Augustin GmbH	Germany	Am Apfelbäumchen 4a	Sankt Augustin	53757	Ordinary	100	100
AniCura Krefeld GmbH	Germany	Saumstraße 5-8	Krefeld	47805	Ordinary	100	100
AniCura Berlin-Biesdorf GmbH	Germany	Alt-Biesdorf 22	Berlin	12683	Ordinary	100	100
AniCura Braunschweig GmbH	Germany	Bockshornweg 71	Braunschweig	38114	Ordinary	100	100
AniCura Kiel GmbH	Germany	Kirchhofallee 70	Kiel	24114	Ordinary	100	100
AniCura Eckernförde GmbH	Germany	Noorstrasse 5	Eckenförde	24340	Ordinary	100	100
AniCura Weiterstadt GmbH	Germany	Darmstädter Straße 11-13	Weiterstadt	64331	Ordinary	100	100
AniCura Stuttgart GmbH	Germany	Hermann-Fein-Straße 15	Stuttgart	70599	Ordinary	-	100
AniCura Frankfurt GmbH	Germany	Juliusstraße 12	Frankfurt	60487	Ordinary	100	100
Bodensee NewCo 28 GmbH	Germany	Marienplatz 61	Ravensburg	88212	Ordinary	100	100
Bodensee NewCo 29 GmbH	Germany	Marienplatz 61	Ravensburg	88212	Ordinary	100	100
Bodensee NewCo 30 GmbH	Germany	Marienplatz 61	Ravensburg	88212	Ordinary	100	100
AniCura Quickborn GbR	Germany	Himmelsmoorchaussee 42	Quickborn	25451	Ordinary	100	100
AniCura Stockelsdorf GbR	Germany	Ahrensböker Straße 74	Stockelsdorf	23617	Ordinary	100	100
AniCura Kiel GbR	Germany	Kirchhofallee 70	Kiel	24114	Ordinary	-	60

Docusign Envelope ID: 1890463A-7409-41D6-949B-06B8014673BF

31 List of companies (continued)

Subsidiary undertakings	Country of incorporation	Street address of the hospital	City/Town	Postal code	Class of shares held	Proportion of voting rights and shares held current year	Proportion of voting rights and shares held prior year
Tierklinik Düsseldorf GmbH	Germany	Münsterstr 359	Düsseldorf	40470	Ordinary	100	-
AniCura Italy Holding S.R.L.	Italy	Via Felice Casati, 20	Milano	20124	Ordinary	100	100
Clinica Veterinaria Borghesiana S.R.L.	Italy	Via di Vermicino 96	Roma	00133	Ordinary	100	100
Ospedale veterinario Pomezia SRL	Italy	Via Castelli Romani 54	Pomezia (RM)	00071	Ordinary	100	100
Nuovo Ospedale Veterinario Ardeatino S.R.L.	Italy	Via Andrea Millevoi 71	Roma	00178	Ordinary	100	100
AniCura Netherlands B.V.	Netherlands	H.J.E. Wenckebackweg 123	Amsterdam	1096 AM	Ordinary	100	100
AniCura Dierenklinieken B.V.	Netherlands	Smeenkhof 12	Deventer	7429 AX	Ordinary	100	100
AniCura Dierenkliniek Sleeuwijk B.V	Netherlands	Loevestein 2	Sleeuwijk	4254 EH	Ordinary	66.67	66.67
MCD AniCura B.V.	Netherlands	Isolatorweg 45	Amsterdam	1014 AS	Ordinary	100	100
Medisch Centrum voor Dieren B.V.	Netherlands	Isolatorweg 45	Amsterdam	1014 AS	Ordinary	69.36	69.36
Dierencrematoria Nederland B.V.	Netherlands	Volgerlandseweg 6	Numansdorp	3281 KV	Ordinary	100	100
Gezelschapsdierenkliniek De Eenhoorn B.V	Netherlands	Ommelseweg 49	Asten	5721 WT	Ordinary	100	-
Heike Dierrijk Klinieken B.V	Netherlands	Zandven 41	Veldhoven	5508 RN	Ordinary	100	-
AniCura AS	Norway	Hoffsveien 70C	Oslo	0377	Ordinary	100	100
AniCura Online As	Norway	Hoffsveien 70C	Oslo	0377	Ordinary	100	100
AniCura Poland sp. z o. o.	Poland	Ul. Grzybowska 2/29	Warszawa	00-131	Ordinary	100	100
Animal Care Center sp. z o.o.	Poland	ul. Sarmacka 9	Warszawa	02-972	Ordinary	100	-
AniCura Aksvet	Poland	ul. Sosnowa 34	Oława	55-200	Ordinary	100	-
ANICURA HOSPITAL VETERINÁRIO DA SANTA MARIN	Portugal	Rua Dom Henrique de Cernache 185	Vila Nova de Gaia	4400-625	Ordinary	-	100
AniCura Portugal, Lda	Portugal	Avenida da Liberdade 38, 1 andar, Santo Antonio	Lisboa	1250 145	Ordinary	100	100
ANICURA AVEIRO HOSPITAL VETERINÁRIO	Portugal	Av. Da Universidade, 215 ,	Aveiro	3810-489	Ordinary	-	100
Altomedvet - Clinica Veterinaria, Unipessoal Lda	Portugal	Rua da Eira 26	Oerias	1495-050	Ordinary	70	70
Hospital Veterinario Restelo Lda	Portugal	Rua Gregório Lopes, Lote 1513	Lisbon	1400-195	Ordinary	70	70

MARS PET SERVICES UK LIMITED

NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 28 DECEMBER 2024

31 List of companies (continued)

Subsidiary undertakings	Country of incorporation	Street address of the hospital	City/Town	Postal code	Class of shares held	Proportion of voting rights and shares held current year	Proportion of voting rights and shares held prior year
Pet Restelo - Artigo Para Animais De Companhia, Unipe	Portugal	Rua Gregório Lopes, Lote 1513	Lisbon	1400-195	Ordinary	70	70
AniCura Algarve Hospital Veterinário Sociedade Unipess	Portugal	Avenida Calouste Gulbenkian loja c n66, 800-072	Algarve	800-072	Ordinary	-	100
CHV CENTRO HOSPITALAR VETERINÀRIO, LDA.	Portugal	Rua Manuel Pinto de Azevedo 118	Porto	4100-320	Ordinary	-	100
Hospital Veterinário Vasco da Gama Lda.	Portugal	Rotunda das Oliveiras Loja 1-A	Lisbon	1990-426	Ordinary	-	100
Clínica Veterinária Arco do Cego, LDA	Portugal	Rua de Dona Filipa de Vilhena 4	Lisbon	1000-135	Ordinary	-	100
Alma Veterinária, LDA	Portugal	Praceta Estado da Baia 4	Cacem	2735596	Ordinary	-	100
Hospital Vetmafra, LDA	Portugal	Rua Quintino António Gomes 12	Mafra	2640-402	Ordinary	-	100
AniCura Animais	Portugal	R. dos Milheirados, nº 21, São Pedro de Fins	Maia	4425-504	Ordinary	100	-
A&A Medical Vet	Romania	Str. Brasov, Nr.25I,	Bucharest		Ordinary	99.9	99.9
Alfa-BK LLC	Russian Federation	Mitinskaya street, building 55/1	Moscow	125310	Ordinary	100	100
AniCura Holding RUS LLC	Russian Federation	Mitinskaya street, building 55/1	Moscow	125310	Ordinary	100	100
Beliy Klik-M LLC	Russian Federation	Isakovskogo street, building 2	Moscow	123181	Ordinary	100	100
Veterinarnaya Kilnika MIV LLC	Russian Federation	1-Y Nagatinskiy Proyezd, building 5/1	Moscow	115533	Ordinary	100	100
VK Center LLC	Russian Federation	Tsvetnoy Blvd, building 11/1	Moscow	127051	Ordinary	100	100
VK Center Plus LLC	Russian Federation	Tsyurupy street, building 13	Moscow	117418	Ordinary	100	100
HardWood VetCare j. s. a.	Slovakia	Stromová 54	Bratislava	831 01	Ordinary	100	-
NeuroVet s.r.o.	Slovakia	Bratislavská 2196/32	Trenčín	911 05	Ordinary	100	-
PetStar Košice s.r.o.	Slovakia	Stromová 54	Bratislava	831 01	Ordinary	100	-
Sibra s.r.o.	Slovakia	Na vrátkach 13	Bratislava	841 02	Ordinary	100	-
Vetanimal Košice s.r.o.	Slovakia	Stromová 54	Bratislava	831 01	Ordinary	100	-
Veterinárna klinika Planet s.r.o.	Slovakia	Popradská 11877/32	Bratislava	821 06	Ordinary	100	-
Veterinárne diagnostické centrum s.r.o.	Slovakia	Stromová 54	Bratislava	831 01	Ordinary	100	-
VetPoint s.r.o.	Slovakia	Panónska cesta 38/A	Bratislava	851 04	Ordinary	100	-
Anicura Emvet Emergencia Veterinarias, S.L.U.	Spain	Paseo María Agustín 67	Zaragosa	50004	Ordinary	100	100

Docusign Envelope ID: 1890463A-7409-41D6-949B-06B8014673BF

31 List of companies (continued)

Subsidiary undertakings	Country of incorporation	Street address of the hospital	City/Town	Postal code	Class of shares held	Proportion of voting rights and shares held current year	Proportion of voting rights and shares held prior year
HOSPITAL VETERINARIO LA CORRALIZA, S.L.U	Spain	Carretera de Cabanillas km 1.9	Tudela	31500	Ordinary	100	100
Anicura Cruz Verde Centro Veterinario, S.L.	Spain	Calle Rondilla Cruz Verde, 140	Cdad. Real	13600	Ordinary	51	51
AniCura Abros Hospital Veterinario s.l.	Spain	Parque Emprearial Pereiro De Aguilar 2A, 32A	Ourense	32710	Ordinary	100	100
AniCura Hospital Veterinario Buenavista Sl	Spain	Calle Rafael Altamira, 3 Bajo	Asturias	33006	Ordinary	100	100
AniCura Spain Holding S.L	Spain	Paseo De La Castellana 43	Madrid	28046	Ordinary	100	100
AniCura Uribe Kosta Centro Veterinario Sl	Spain	Loiola Ander Deuna, 36	Sopelana - Bizkaia	48600	Ordinary	100	100
Centro Veterinario San Fermin S.L.P.	Spain	Calle Nueva 27, Aranguren Muntilva Alta	Navarra	31192	Ordinary	100	100
Hospital Veterinario Marina Baixa S.L.	Spain	Passeig De La Mitja Llegua 17	Alacant	3580	Ordinary	100	100
AniCura Constitucion Hospital Veterinario SL	Spain	Calle Alcudia de Crespins 12 bajo izq, 46019	Valencia	46019	Ordinary	100	100
Servicios Veterinarios Lepanto S.L.	Spain	Calle Barcelona 40, 41927	Mairena del Aljarafe	41927	Ordinary	100	100
Imavet Galicia S.L.P.	Spain	Rúa Hedras 1	A Coruña	15895	Ordinary	100	100
AniCura Indautxu Hospital Veterinario, S.L.U	Spain	San Mames Zumarkalea, 36, 38	Bizkaia	48010	Ordinary	100	95
AniCura AB	Sweden	Vendevagen 89	Danderyd	182 32	Ordinary	100	100
Anicura Sweden AB	Sweden	Vendevagen 89	Danderyd	182 32	Ordinary	100	100
AniCura Holding AB	Sweden	Vendevagen 89	Danderyd	182 32	Ordinary	100	100
AniCura Online AB	Sweden	Vendevagen 89	Danderyd	182 32	Ordinary	100	100
AniCura Switzerland AB	Sweden	Vendevägen 89	Danderyd	182 32	Ordinary	100	100
AniCura TC AB	Sweden	Vendevagen 89	Danderyd	182 32	Ordinary	100	100
Mälardalens Smådjurskrematorium AB	Sweden	Gottsta 22	Vasteras	72598	Ordinary	100	100
Rosenholm 2 Katrineholm AB	Sweden	Rinkebyvagen 21 B	Danderyd	182 36	Ordinary	100	100
TTM Lokalutveckling AB	Sweden	Olof Palmes Torg 10	Vasteras	723 34	Ordinary	100	100
Uppsala Veterinärmottagning AB	Sweden	Libro Ringväg 6	Uppsala	752 28	Ordinary	100	100
Öresunds Veterinärklinik i Lund AB	Sweden	Gustavshemsvägen 1	Lund	227 64	Ordinary	100	-

Docusign Envelope ID: 1890463A-7409-41D6-949B-06B8014673BF

31 List of companies (continued)

Subsidiary undertakings	Country of incorporation	Street address of the hospital	City/Town	Postal code	Class of shares held	Proportion of voting rights and shares held current year	Proportion of voting rights and shares held prior year
AniCura Odalbygden 8 Jagarvallen AB	Sweden	Jagarvallsvagen 2	Linkoping	584 22	Ordinary	100	100
AniCura AOI Center AG	Switzerland	Rothusstrasse 2A	Hünenberg	6331	Ordinary	100	100
AniCura Kleintierpraxis Sursee AG	Switzerland	Eichenstrasse 1	Sursee	6210	Ordinary	100	100
Tierarztpraxis am Homberg GmbH	Switzerland	Dorfstrasse 18	Wangen bei Olten	4612	Ordinary	100	100
Tierklinik am Kreis AG	Switzerland	Zaunweg 11	Netstal	8754	Ordinary	100	100
AniCura Tierklinik Thun AG	Switzerland	Burgerstrasse 11	Thun	3600	Ordinary	100	100
Kleintierpraxis Laupeneck GmbH	Switzerland	Laupenstrasse 33	Bern	3008	Ordinary	100	100
Vetconcept S.A.	Switzerland	Rue Marterey 52	Lausanne	1005	Ordinary	100	100
Linnaeus Group Limited	England & Wales	Friars Gate, 1011 Stratford Road	Shirley	B90 4BN	Ordinary	100	100
Linnaeus Group Bidco Limited	England & Wales	Friars Gate, 1011 Stratford Road	Shirley	B90 4BN	Ordinary	100	100
Linnaeus Veterinary Limited	England & Wales	Friars Gate, 1011 Stratford Road	Shirley	B90 4BN	Ordinary	100	100
Linnaeus Referrals Limited	England & Wales	Friars Gate, 1011 Stratford Road	Shirley	B90 4BN	Ordinary	100	100
Dick White Referrals Limited	England & Wales	Station Farm London Road	Newmarket	CB8 0UH	Ordinary	100	100
Anderson Moores Veterinary Specialists Limited	England & Wales	Friars Gate, 1011 Stratford Road	Shirley	B90 4BN	Ordinary	100	100
Northwest Veterinary Specialists Limited	England & Wales	Friars Gate, 1011 Stratford Road	Shirley	B90 4BN	Ordinary	100	100
Eye-vet Limited	England & Wales	Friars Gate, 1011 Stratford Road	Shirley	B90 4BN	Ordinary	100	100
Veterinary Specialists (Scotland) Limited	Scotland	1 Deerpark Road	Livingston	EH54 8AG	Ordinary	100	100
St Anne's Vets Limited	England & Wales	Friars Gate, 1011 Stratford Road	Shirley	B90 4BN	Ordinary	100	100
City Vets (Exeter) Limited	England & Wales	Friars Gate, 1011 Stratford Road	Shirley	B90 4BN	Ordinary	100	100
Wildbore Veterinary Limited	England & Wales	Friars Gate, 1011 Stratford Road	Shirley	B90 4BN	Ordinary	100	100
St. John Cooper Consultancy Limited	England & Wales	Friars Gate, 1011 Stratford Road	Shirley	B90 4BN	Ordinary	100	100
Cotswold Veterinary Group Limited	England & Wales	Friars Gate, 1011 Stratford Road	Shirley	B90 4BN	Ordinary	100	100
Peak Veterinary Practice Limited	England & Wales	Friars Gate, 1011 Stratford Road	Shirley	B90 4BN	Ordinary	100	100
Palmerston Veterinary Group Limited	England & Wales	Friars Gate, 1011 Stratford Road	Shirley	B90 4BN	Ordinary	100	100

MARS PET SERVICES UK LIMITED

NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 28 DECEMBER 2024

31 List of companies (continued)

Subsidiary undertakings	Country of incorporation	Street address of the hospital	City/Town	Postal code	Class of shares held	Proportion of voting rights and shares held current year	Proportion of voting rights and shares held prior year
Forest Veterinary Centre Limited	England & Wales	Friars Gate, 1011 Stratford Road	Shirley	B90 4BN	Ordinary	100	100
Wilbury Veterinary Services Limited	England & Wales	Friars Gate, 1011 Stratford Road	Shirley	B90 4BN	Ordinary	100	100
WSHPM Limited	England & Wales	Friars Gate, 1011 Stratford Road	Shirley	B90 4BN	Ordinary	100	100
Parkhill Vets Limited	England & Wales	Friars Gate, 1011 Stratford Road	Shirley	B90 4BN	Ordinary	100	100
My Pet Vets Leight Limited	England & Wales	Friars Gate, 1011 Stratford Road	Shirley	B90 4BN	Ordinary	100	100
Colne Valley Veterinary Pracrice Limited	England & Wales	Off Maudlyn Road	Colchester	CO1 2GU	Ordinary	100	-
J T Vets Limited (Edgewood)	England & Wales	Friars Gate, 1011 Stratford Road	Shirley	B90 4BN	Ordinary	100	-
Bay Vets Limited	England & Wales	Friars Gate, 1011 Stratford Road	Shirley	B90 4BN	Ordinary	100	-
Baldrand Bay Holdings Limited	England & Wales	Friars Gate, 1011 Stratford Road	Shirley	B90 4BN	Ordinary	100	-
Focus Referrals Limited	England & Wales	Friars Gate, 1011 Stratford Road	Shirley	B90 4BN	Ordinary	100	-
RVCL Holding Company Limited	England & Wales	12a Ayston Road	Oakham	LE15 9RL	Ordinary	100	-
Rutco Holding Company Limited	England & Wales	Friars Gate, 1011 Stratford Road	Shirley	B90 4BN	Ordinary	100	-
Rutland Veterinary Centre	England & Wales	12a Ayston Road	Oakham	LE15 9RL	Ordinary	100	-
Lyddington Holding Compnay Limited	England & Wales	12a Ayston Road	Oakham	LE15 9RL	Ordinary	100	-
CPM (Cheshire) Limited (Victoria Vets)	England & Wales	Staverton Court	Cheltenham	GL51 0UX	Ordinary	100	-
Primrose Hill Veterinary Clinic Limited	Republic of Ireland	10 Earlsfort Terrace	Dublin	D02 T380	Ordinary	100	100
Blackrock Vets Limited	Republic of Ireland	10 Earlsfort Terrace	Dublin	D02 T380	Ordinary	100	100
Carton Veterinary Clinic Limited	Republic of Ireland	10 Earlsfort Terrace	Dublin	D02 T380	Ordinary	100	100
Firhouse Veterinary Clinic Company Limited	Republic of Ireland	10 Earlsfort Terrace	Dublin	D02 T380	Ordinary	100	100
Hermitage Veterinary Clinic Company Limited,	Republic of Ireland	10 Earlsfort Terrace	Dublin	D02 T380	Ordinary	100	100
Linnaeus Veterinary Ireland Limited	Republic of Ireland	10 Earlsfort Terrace	Dublin	D02 T380	Ordinary	100	100
Nutgrove Veterinary Limited	Republic of Ireland	10 Earlsfort Terrace	Dublin	D02 T380	Ordinary	100	-